

CITATION REPORT

List of articles citing

Remdesivir for the Treatment of Covid-19 - Final Report

DOI: 10.1056/NEJMoa2007764

New England Journal of Medicine, 2020, 383, 1813-1826.

Source: <https://exaly.com/paper-pdf/85002485/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2294	Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. 2020 , 7, ofaa320		
2293	Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. 2020 , 7, ofaa345		21
2292	Prediction is very difficult, especially if it's about the future ¹ . 2020 , 42, 443-444		3
2291	Treatment of coronavirus disease 2019. 2020 , 15, 336-340		3
2290	Overview of coronavirus disease 2019: Treatment updates and advances. 2020 , 83, 805-808		7
2289	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. 2020 , 76, 1350-1367		36
2288	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). 2020 , 29,		50
2287	COVID-19 in patients undergoing chronic kidney replacement therapy and kidney transplant recipients in Scotland: findings and experience from the Scottish renal registry. 2020 , 21, 419		18
2286	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. 2020 , 7, 546		5
2285	Endothelial Cell Contributions to COVID-19. 2020 , 9,		12
2284	Crystal Structure of Non-Structural Protein 10 from Severe Acute Respiratory Syndrome Coronavirus-2. 2020 , 21,		29
2283	Remdesivir and COVID-19. 2021 , 190, 1237-1238		19
2282	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. 2020 , 80, 1929-1946		45
2281	Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. 2020 , 10, 17073		16
2280	Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. 2020 , 371, m4057		64
2279	Reflections on the Collaborative Fight Against COVID-19. 2020 , 7, 565		
2278	Treatment for COVID-19: An overview. 2020 , 889, 173644		98

2277	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar. 2020 , 76, 1999-2010	13
2276	SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Unit. 2020 , 10, 1722	3
2275	COVID-19 associated complications and potential therapeutic targets. 2020 , 886, 173548	10
2274	Interferon β 1 in treatment of severe COVID-19: A randomized clinical trial. 2020 , 88, 106903	82
2273	Healthcare system approach to managing COVID-19 in a metropolitan community in Kentucky. 2020 , 99, e22254	5
2272	Acute Kidney Injury in COVID-19: The Chinese Experience. 2020 , 40, 430-442	17
2271	Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. 2020 , 56,	75
2270	Mining the past to treat the present, ever mindful of the future: Low-dose radiotherapy and COVID-19 pneumonia. 2020 , 126, 5017-5021	3
2269	COVID-19 in the Pediatric Population-Review and Current Evidence. 2020 , 22, 29	12
2268	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. 2020 , 27, 100547	17
2267	Favipiravir: A new and emerging antiviral option in COVID-19. 2020 , 76, 370-376	140
2266	Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis. 2020 , 11, 540187	2
2265	Leveraging the advances in HIV for COVID-19. 2020 , 396, 943-944	3
2264	Remdesivir and COVID-19. 2020 , 396, 953-954	5
2263	A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19. 2020 , 98, 233-240	65
2262	Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. 2020 , 37, 101734	66
2261	The BASIC Score: A Useful Tool to Identify Patients at High Risk of Early Progression to Severe Coronavirus Disease 2019. 2020 , 7, ofaa405	6
2260	The use of remdesivir outside of clinical trials during the COVID-19 pandemic. 2020 , 13, 61	2

2259	Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study. 2020 , 9, 943-952	12
2258	Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. 2020 , 28, 586-601.e6	192
2257	COVID-19 in children: what did we learn from the first wave?. 2020 , 30, 438-443	6
2256	A review on coronavirus survivability on material surfaces: present research scenarios, technologies and future directions. 2020 , 36, 1226-1239	7
2255	Pandemic treatments on trial: the bigger picture.. 2020 , 56,	2
2254	Early management of critically ill patients with COVID-19. 2020 , 1, 1418-1426	0
2253	Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence. 2020 , 196, 638-640	8
2252	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2333-2344	59.2 739
2251	Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. 2020 , 9, 2433-2445	86
2250	The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. 2020 , 95,	91
2249	Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. 2020 , 17, 154	38
2248	Critical Care Demand and Intensive Care Supply for Patients in Japan with COVID-19 at the Time of the State of Emergency Declaration in April 2020: A Descriptive Analysis. 2020 , 56,	1
2247	Strategies and Advances in Combating COVID-19 in China. 2020 , 6, 1076-1084	8
2246	Síndrome inflamatorio multisistémico en niños con COVID-19: una visión desde la reumatología. 2020 , 28, 289-289	
2245	COVID-19 in a patient with a flare of systemic lupus erythematosus: A rare case-report. 2020 , 31, 101252	7
2244	Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase. 2020 , 22, 8430-8435	10
2243	Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. 2020 , 10, 17806	27
2242	Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. 2021 , 73, e4082-e4089	13

2241	Engineered ACE2 receptor traps potentially neutralize SARS-CoV-2. 2020 , 117, 28046-28055	110
2240	What Does CME Accreditation Stand for?. 2020 , 9, 1822665	1
2239	Covid-19, Ebola, and HIV - Leveraging Lessons to Maximize Impact. <i>New England Journal of Medicine</i> , 2020 , 383, e106	59.2 9
2238	[SARS-COV-2 myocarditis. An update]. 2020 , 69, 349-354	1
2237	Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. 2020 , 182, 104927	8
2236	COVID-19 pneumonia in an HIV-positive woman on antiretroviral therapy and undetectable viral load in Porto Alegre, Brazil. 2020 , 24, 455-457	8
2235	Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. 2020 , 8, 1192-1200	63
2234	Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. 2020 , 117, 26946-26954	36
2233	Molecular dynamics analysis predicts ritonavir and naltrexone strongly block the SARS-CoV-2 spike protein-hACE2 binding. 2020 , 1-10	7
2232	A Review of Remdesivir for COVID-19: Data to Date. 2020 , 28, 332-334	5
2231	COVID-19 disparities: An urgent call for race reporting and representation in clinical research. 2020 , 19, 100630	24
2230	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. 2021 , 73, e3996-e4004	43
2229	Projected supportive effects of Pycnogenol in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection. 2020 , 56, 106191	2
2228	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. 2020 , 41, 1006-1022	46
2227	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
2226	Imposed mutational meltdown as an antiviral strategy. 2020 , 74, 2549-2559	6
2225	Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report. 2020 , 8, 2990-2994	3
2224	Remdesivir against COVID-19 and Other Viral Diseases. 2020 , 34,	97

2223	The potential of lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19. 2020 , 15, 609-624	13
2222	Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19. 2020 , 21, 100438	8
2221	COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. 2020 , 16, 747-764	229
2220	High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2. 2020 , 25, 1152-1161	21
2219	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. 2020 , 10, CD013600	64
2218	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. 2020 , 2, 1-23	45
2217	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2020 , 140, 86-104	14
2216	Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery. 2020 , 19, 4698-4705	9
2215	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. 2020 , 370,	261
2214	Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity. 2020 , 64,	6
2213	Convalescent Blood Products in COVID-19: A Narrative Review. 2020 , 7, 2049936120960646	2
2212	The Impacts of Antivirals on the Coronavirus Genome Structure and Subsequent Pathogenicity, Virus Fitness and Antiviral Design. 2020 , 8,	3
2211	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. 2020 , 8,	3
2210	Low-dose whole-lung radiation for COVID-19 pneumonia: Planned day 7 interim analysis of a registered clinical trial. 2020 , 126, 5109-5113	49
2209	Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. 2020 , 40, 1166-1171	21
2208	What GI Physicians Need to Know During COVID-19 Pandemic. 2021 , 66, 2865-2875	6
2207	Management Considerations for the COVID-19 Patient with Severe Disease: a Case Scenario and Literature Review. 2020 , 1-7	1
2206	Remdesivir and COVID-19 - Authors' reply. 2020 , 396, 954	1

2205	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. 2020 , 182, 104924	20
2204	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. 2020 , 183, 996-1012.e19	711
2203	Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. 2020 , 18, 2200-2208	8
2202	Magnetic particle targeting for diagnosis and therapy of lung cancers. 2020 , 328, 776-791	29
2201	Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. 2020 , 81, 952-960	42
2200	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. 2020 , 32, 3159-3166	9
2199	Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations. 2020 , 23, 1409-1422	6
2198	Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. 2020 , 259, 118275	44
2197	The FDA and the Importance of Trust. <i>New England Journal of Medicine</i> , 2020 , 383, e148	59.2 7
2196	Reply to Olivera and Mallat. 2021 , 73, e272-e273	
2195	Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan. 2021 , 73, e3677-e3689	60
2194	Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. 2021 , 73, e1762-e1765	47
2193	[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. 2020 , 155, 375-381	5
2192	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. 2020 , 17, 543-558	560
2191	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". 2020 , 189, 1442-1443	5
2190	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. 2020 , 6, 2304-2318	25
2189	Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. 2021 , 87, 3439-3450	14
2188	Mechanisms of Stroke in COVID-19. 2020 , 49, 451-458	99

2187	Extracorporeal Membrane Oxygenation for COVID-19. 2020 , 15, 306-313	2
2186	Immune-mediated approaches against COVID-19. 2020 , 15, 630-645	178
2185	COVID-19 in lung transplant patients: A case series. 2020 , 20, 3234-3238	20
2184	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. 2020 , 190, e274-e276	13
2183	A Randomized Clinical Trial of the Efficacy and Safety of Interferon β 1a in Treatment of Severe COVID-19. 2020 , 64,	170
2182	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. 2020 , 18, 367-375	15
2181	Improving Clinical Trial Enrollment - In the Covid-19 Era and Beyond. <i>New England Journal of Medicine</i> , 2020 , 383, 1406-1408	59.2 27
2180	Treatment of COVID-19 - Evidence-Based or Personalized Medicine?. 2020 ,	3
2179	Covid-19: Experts criticise claim that remdesivir cuts death rates. 2020 , 370, m2839	4
2178	Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. 2020 , 11, 1013	31
2177	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. 2020 , 53, 100719	79
2176	Waste in COVID-19 clinical trials conducted in western Europe. 2020 , 81, 91-93	7
2175	Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19. 2020 , 21, 1813-1819	6
2174	Endpoints for randomized controlled clinical trials for COVID-19 treatments. 2020 , 17, 472-482	28
2173	Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. 2020 , 16, 617-629	24
2172	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. 2020 , 21,	22
2171	Clinical presentation and management of COVID-19. 2020 , 213, 134-139	24
2170	Pathogenesis and management of myocardial injury in coronavirus disease 2019. 2020 , 22, 1994-2006	19

2169	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374	9
2168	The dynamic treatment of SARS-CoV-2 disease. 2020 , 33, 572-579	1
2167	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. 2020 , 12, 483-497	22
2166	Communicating Science in the Time of a Pandemic. 2020 ,	29
2165	Rapid production of clinical-grade SARS-CoV-2 specific T cells. 2020 , 3, e101	13
2164	Opportunities for biomaterials to address the challenges of COVID-19. 2020 , 108, 1974-1990	30
2163	SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. 2020 , 23, e25573	29
2162	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. 2020 , 46, 2265-2283	27
2161	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. 2020 , 9, 525-536	14
2160	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). 2020 , 7, 572485	10
2159	Current and Future Direct-Acting Antivirals Against COVID-19. 2020 , 11, 587944	10
2158	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. 2020 , 2020, 8865954	28
2157	Phenotypes and personalized medicine in the acute respiratory distress syndrome. 2020 , 46, 2136-2152	36
2156	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a. 2020 , 28, 2691-2702	9
2155	Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. 2020 , 34, 525-541	11
2154	The Rationale for Angiotensin Receptor Nephilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. 2020 , 21,	11
2153	The unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?. 2020 , 20, 862	2
2152	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. 2021 , 72, e1130-e1143	14

2151	Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors. 2020 , 95, 2343-2349	3
2150	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. 2020 , 27, 434-441	2
2149	Rescue Treatment With High-Dose Gaseous Nitric Oxide in Spontaneously Breathing Patients With Severe Coronavirus Disease 2019. 2020 , 2, e0277	8
2148	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. 2020 , 18, 3774-3787	11
2147	Piecewise-constant optimal control strategies for controlling the outbreak of COVID-19 in the Irish population. 2020 , 330, 108496	20
2146	Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019. 2020 , 13, 221-223	2
2145	[COVID-19 pneumonia]. 2020 , 15, 1-11	2
2144	COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis. 2020 , 14, 5097-5108	4
2143	Neuromuscular Diseases Care in the Era of COVID-19. 2020 , 11, 588929	13
2142	Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review. 2021 , 87, 2663-2684	8
2141	Recommendations for treatment of critically ill patients with COVID-19 : Version 3 S1 guideline. 2020 , 1	11
2140	Repurposing Anti-Cancer Drugs for COVID-19 Treatment. 2020 , 14, 5045-5058	14
2139	Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. 2020 , 2,	3
2138	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. 2020 , 7, 2054358120967845	9
2137	Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. 2020 , 7, 2054358120970713	2
2136	Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. 2020 , 21, 927	3
2135	Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. 2020 , 20, 897	23
2134	Assessment of Risks Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Experimental Human Infection Studies. 2021 , 73, e1228-e1234	6

2133	Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development. 2020 , 9,	0
2132	The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access. 2020 , 324, 2151-2152	6
2131	The Assessment of Convalescent Plasma Efficacy against COVID-19. 2020 , 1, 66-77	14
2130	How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. 2020 , 173, 632-637	20
2129	Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study. 2020 , 161, 105290	33
2128	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. 2020 ,	57
2127	COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies. 2020 , 11, 1481-1495	6
2126	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. 2020 , 155, 375-381	1
2125	FDA Approval of Remdesivir - A Step in the Right Direction. <i>New England Journal of Medicine</i> , 2020 , 383, 2598-2600	59.2 78
2124	Declines in Mortality Over Time for Critically Ill Adults With Coronavirus Disease 2019. 2020 , 48, e1382-e1384	41
2123	Remdesivir: a pendulum in a pandemic. 2020 , 371, m4560	2
2122	Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis. 2020 , 6,	
2121	FDA efficiency for approval process of COVID-19 therapeutics. 2020 , 15, 73	5
2120	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. 2020 , 8,	14
2119	USA stockpiling of remdesivir: How should the world respond?. 2020 , 9, 1243-1246	
2118	SARS-CoV-2 Inhibition by Sulfonated Compounds. 2020 , 8,	9
2117	The "sex gap" in COVID-19 trials: a scoping review. 2020 , 29, 100652	21
2116	Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. 2021 , 35, 269-292	4

2115	Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19. 2020 , 175, 106188	20
2114	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). 2020 , 4, 121-131	
2113	Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. 2020 , 25,	34
2112	Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. 2020 , 228, 122-128	6
2111	In fatal COVID-19, the immune response can control the virus but kill the patient. 2020 , 117, 30009-30011	15
2110	Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients. 2020 , 2, e0232	6
2109	Dangerous Pathogens as a Potential Problem for Public Health. 2020 , 56,	6
2108	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,	4
2107	ATS Core Curriculum 2020. Adult Pulmonary Medicine. 2020 , 1, 416-435	
2106	Effect of the early use of antivirals on the COVID-19 pandemic. A computational network modeling approach. 2020 , 140, 110168	8
2105	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. 2020 , 173, 623-631	298
2104	Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection. 2020 , 13, 608-614	7
2103	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. 2020 , 11, 559996	1
2102	Coronavirus Infection of the Central Nervous System: Animal Models in the Time of COVID-19. 2020 , 7, 584673	2
2101	The importance of patients' case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease. 2020 , 100, 67-74	7
2100	Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. 2020 , 11, 776-782	50
2099	Ophthalmic manifestations of coronavirus disease 2019 and ocular side effects of investigational pharmacologic agents. 2020 , 31, 403-415	3
2098	The COVID-19 pandemic: A community approach. 2020 , 34, e14059	7

2097	The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. 2020 , 21, 225	134
2096	A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. 2020 , 14, 3215-3222	33
2095	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. 2020 , 30, 1-13	12
2094	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. 2020 , 88, 106885	20
2093	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114	11
2092	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. 2020 , 147, 12-17	19
2091	Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities. 2020 , 17, 533-535	22
2090	Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm. 2020 , 52, 531-539	
2089	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. 2020 , 21, 1821-1849	3
2088	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. 2020 , 13, 957-975	5
2087	Cyclosporine and COVID-19: Risk or favorable?. 2020 , 20, 2975-2982	18
2086	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. 2020 , 1, 234-243	29
2085	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. 2020 , 11, 1949	163
2084	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. 2020 , 13, 1187-1195	46
2083	After 62 years of regulating immunity, dexamethasone meets COVID-19. 2020 , 20, 587-588	59
2082	Racial Disproportionality in Covid Clinical Trials. <i>New England Journal of Medicine</i> , 2020 , 383, e59	59.2 66
2081	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. 2020 , 35, 725-733	20
2080	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. 2020 , 15, e0236778	14

2079	Using "old" medications to fight new COVID-19: Re-purposing with a purpose. 2020 , 146, 41-42	1
2078	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. 2021 , 73, e4166-e4174	72
2077	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. 2020 , 10, 1514-1527	80
2076	COVID-19: A Perspective from Clinical Neurology and Neuroscience. 2020 , 26, 387-391	10
2075	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. 2020 , 13,	47
2074	Racial and Ethnic Disparities in Disease Severity on Admission Chest Radiographs among Patients Admitted with Confirmed Coronavirus Disease 2019: A Retrospective Cohort Study. 2020 , 297, E303-E312	38
2073	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. 2020 , 72, 1864-1872	108
2072	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
2071	COVID-19 manifestations in children. 2020 , 10, 186-188	
2070	Long-acting antiretroviral therapy. 2020 , 19, 826-827	8
2069	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2041-2052	59.2 620
2068	The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions. 2020 , 11, 1692	13
2067	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. 2020 , 11, 820	12
2066	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. 2020 , 72, 1971-1980	35
2065	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. 2020 , 6, 1-13	10
2064	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. 2020 , 2, 100159	22
2063	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. 2020 , 26, 1983-1994	26
2062	Drug Discovery Strategies for SARS-CoV-2. 2020 , 375, 127-138	51

2061	Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. 2020 , 15, 2085-2102	36
2060	COVID-19 and the Kidneys: An Update. 2020 , 7, 423	48
2059	Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US. 2020 , 324, 859-870	252
2058	Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. 2020 , 9, e1159	12
2057	[COVID-19 pneumonia]. 2020 , 61, 793-803	5
2056	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). 2020 , 58, 102887	78
2055	Remdesivir for severe covid-19: a clinical practice guideline. 2020 , 370, m2924	58
2054	Drug treatments for covid-19: living systematic review and network meta-analysis. 2020 , 370, m2980	331
2053	SARS-CoV-2: characteristics and current advances in research. 2020 , 17, 117	39
2052	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. 2020 , 14, 3001-3013	15
2051	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. 2020 , 28, 745-764	9
2050	Mortality in COVID-19 is not merely a question of resource availability. 2020 , 8, 832-833	8
2049	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. 2020 ,	96
2048	Desperate times call for evidence-based measures: Prioritizing science during the COVID-19 pandemic. 2020 , 5, 127-129	
2047	"COVID-19: diagnosis, management and prognosis": a new topical collection of Internal and Emergency Medicine. 2020 , 15, 747-750	10
2046	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. 2020 , 41, 815-829	66
2045	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. 2020 , 9, 561-572	15
2044	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. 2020 , 56, 106129	7

2043	Remdesivir: Remedy the world is waiting for?. 2020 , 76, 250-252	
2042	Diagnostic and Treatment Strategies for COVID-19. 2020 , 21, 222	17
2041	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. 2020 , 885, 173450	9
2040	COVID-19 -Tuberculosis interactions: When dark forces collide. 2020 , 67, S155-S162	21
2039	Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm. 2020 , 3, 613-626	19
2038	COVID-19 and liver disease: An update. 2020 , 43, 472-480	12
2037	Toll-like receptors and COVID-19: a two-faced story with an exciting ending. 2020 , 6, FSO605	62
2036	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. 2020 , 8,	12
2035	The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19. 2020 , 42, e270-e273	3
2034	Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease. 2020 , 16, e1008735	14
2033	Missed Opportunities on Emergency Remdesivir Use. 2020 , 324, 331-332	12
2032	Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. 2020 , 16, 1571-1581	61
2031	Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. 2020 , 190, 2290-2303	144
2030	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. 2020 , 183, 158-168.e14	955
2029	Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history. 2020 , 11, 1015-1023	1
2028	SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. 2020 , 21,	35
2027	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. 2020 , 9,	1
2026	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,	4

2025	Delivering evidence-based critical care for mechanically ventilated patients with COVID-19. 2020 , 8, 756-758	4
2024	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14
2023	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. 2020 , 57, 236-243	23
2022	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. 2020 , 26, 1537-1544	50
2021	Emerging therapeutics for the management of COVID 19. 2020 , 25, 337-351	5
2020	Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches. 2020 , 13, 1067-1072	0
2019	COVID-19 and multisystem inflammatory syndrome in children and adolescents. 2020 , 20, e276-e288	351
2018	COVID-19 and Cardiovascular Health Among Patients with Cancer. 2020 , 22, 171	5
2017	Antivirals for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11	4
2016	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240	4
2015	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. 2020 , 99, 106189	2
2014	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. 2020 , 20, 727-738	56
2013	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. 2020 , 11,	69
2012	Response. 2020 , 158, 2232	
2011	US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?. 2021 , 73, 549-552	1
2010	Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). 2020 , 136, 1025-1029	30
2009	Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. 2020 , 8, 587866	6
2008	Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven. 2020 , 20, 100663	

2007	COVID-19 update: The race to therapeutic development. 2020 , 53, 100733	33
2006	SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. 2020 , 217,	325
2005	Thrombosis and COVID-19: The Potential Role of Nutrition. 2020 , 7, 583080	19
2004	Computational Identification of Human Biological Processes and Protein Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using Protein-Protein Interaction Networks. 2020 , 19, 4553-4566	6
2003	Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). 2021 , 73, e4020-e4024	23
2002	Covid-19: US approves remdesivir despite WHO trial showing lack of efficacy. 2020 , m4120	5
2001	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. 2021 , 110, 64-68	11
2000	[German recommendations for treatment of critically ill patients with COVID-19-version 3]. 2020 , 17, 1-12	3
1999	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980	20
1998	Coronavirus disease 2019: scientific overview of the global pandemic. 2020 , 38, 100800	1
1997	COSMO-RS-Based Descriptors for the Machine Learning-Enabled Screening of Nucleotide Analogue Drugs against SARS-CoV-2. 2020 , 11, 9408-9414	6
1996	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. 2020 , 3, 1165-1175	42
1995	COVID-19-Lessons Learned and Questions Remaining. 2021 , 72, 2225-2240	34
1994	A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. 2020 , 18, 390	21
1993	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. 2020 , 8, 580202	19
1992	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
1991	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
1990	The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. 2020 , 20, 786	61

1989	COVID-19 multidisciplinary high dependency unit: the Milan model. 2020 , 21, 260	14
1988	Dexamethasone and remdesivir: finding method in the COVID-19 madness.. 2020 , 1, e309-e310	13
1987	SARS-CoV-2 viral load is associated with increased disease severity and mortality. 2020 , 11, 5493	360
1986	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. 2020 , 60, 840-851	18
1985	Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. 2020 , 10, e040441	23
1984	Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. 2021 , 31, e2187	36
1983	Intricate interplay between Covid-19 and cardiovascular diseases. 2021 , 31, e2188	3
1982	The importance of overweight in COVID-19: A retrospective analysis in a single center of Wuhan, China. 2020 , 99, e22766	12
1981	Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, and Control Measures. 2020 , 2020, 9121429	10
1980	[Covid-19: clinical aspects and management]. 2020 , 2020, 40-47	2
1979	Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. 2020 , 8, 1170-1172	69
1978	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. 2020 , 56, 106208	15
1977	Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. 2020 , 76, 2334-2348	78
1976	Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease. 2020 , 22, 25335-25343	23
1975	Animal models for SARS-CoV-2 research: A comprehensive literature review. 2021 , 68, 1868-1885	28
1974	Novel Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. 2020 , 28, 1243-1252	3
1973	Remdesivir: US purchase of world stocks sparks new "hunger games," warn observers. 2020 , 370, m2661	3
1972	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. 2020 , 10, e044566	4

1971	Ethically Allocating COVID-19 Drugs Via Pre-approval Access and Emergency Use Authorization. 2020 , 20, 4-17	17
1970	Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study. 2021 , 73, e2995-e3001	40
1969	Severity of COVID-19 in pregnancy: A review of current evidence. 2020 , 84, e13332	15
1968	COVID-19-Related Knowledge, Attitude and Practice Among Hospital and Community Pharmacists in Addis Ababa, Ethiopia. 2020 , 9, 105-112	24
1967	Remdesivir: First Approval. 2020 , 80, 1355-1363	84
1966	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. 2020 , 7, ofaa319	8
1965	Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients. 2020 , 20, 220	3
1964	COVID-19 infection in children and adolescents. 2020 , 81, 1-10	18
1963	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. 2020 , 324, 1298-1306	229
1962	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. 2020 , 324, 1317-1329	386
1961	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. 2020 , 16, 2980-2991	16
1960	The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection. 2020 , 161,	13
1959	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. 2020 , 2, 1-13	26
1958	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. 2020 , 75, 3373-3378	53
1957	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. 2020 , 19, 40	62
1956	Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations. 2020 , 11, 1039	35
1955	Clinical Experience with COVID-19 at a Specialty Orthopedic Hospital Converted to a Pandemic Overflow Field Hospital. 2020 , 1-7	3
1954	"A Chain Only as Strong as Its Weakest Link": An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19. 2020 , 19, 4327-4338	20

1953	Rapid Real-time Tracking of Nonpharmaceutical Interventions and Their Association With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity: The Coronavirus Disease 2019 (COVID-19) Pandemic Pulse Study. 2021 , 73, e1822-e1829	16
1952	A living WHO guideline on drugs for covid-19. 2020 , 370, m3379	275
1951	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
1950	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. 2020 , 396, 959-967	183
1949	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. 2020 , 13,	26
1948	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. 2020 , 205, 2566-2575	9
1947	Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection. 2020 , 9, CD013628	11
1946	Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. 2020 , 10, e041276	20
1945	Towards characterized convalescent plasma for COVID-19: The dose matters. 2020 , 26, 100545	7
1944	COVID-19 clinical trials: learning from exceptions in the research chaos. 2020 , 26, 1671-1672	21
1943	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. 2020 , 10, e041437	24
1942	Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. 2020 , 15, e0239799	127
1941	Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. 2020 , 4, 1178	185
1940	[COVID-19, management, therapeutic and vaccine approaches]. 2020 , 59, 27-33	1
1939	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. 2020 , 183, 1043-1057.e15	454
1938	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials. 2020 , 288, 198137	25
1937	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. 2020 , 20, 3198-3205	31
1936	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2020 , 17, e1003293	36

1935 [COVID-19-a new and many-sided challenge]. **2020**, 61, 773-775

1934	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. 2020 , 38, 2405-2415	10
1933	A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp). 2020 , 1-8	14
1932	Guiding Difficult Decisions on Scarce Investigational Therapeutic Agents in the COVID-19 Pandemic. 2020 , 20, 20-23	2
1931	RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19. 2020 , 111, 3976-3984	21
1930	SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report. 2021 , 25, e13875	7
1929	A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. 2020 , 9,	21
1928	Remdesivir: an antiviral for the treatment of COVID-19. 2020 , 31, 31-33	1
1927	Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. 2020 , 97, 106145	5
1926	Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. 2020 , 370, 725-730	182
1925	Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs. 2020 , 8, 497	10
1924	Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. 2020 , 8, e1249-e1250	18
1923	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. 2020 , 75, 3359-3365	26
1922	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. 2020 , 9, 596-608	18
1921	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. 2020 , 8, 937	10
1920	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 2020 , 63, 13205-13227	18
1919	Human Challenge Studies Are Unlikely to Accelerate Coronavirus Vaccine Licensure Due to Ethical and Practical Issues. 2020 , 222, 1572-1574	5
1918	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). 2020 , 43, 1055-1063	30

1917	Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). 2020 , 15, 1287-1305	52
1916	Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019. 2020 , 11, 1330	
1915	[German recommendations for treatment of critically ill patients with COVID-19-version 3 : S1-guideline]. 2020 , 69, 653-664	9
1914	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. 2020 , 146, 518-534.e1	79
1913	COVID-19 infection and its deadly cytokine storm in a young obese adult. 2020 , 10, 295-298	1
1912	Remdesivir is Effective for Moderately Severe Patients: A Re-Analysis of the First Double-Blind, Placebo-Controlled, Randomized Trial on Remdesivir for Treatment of Severe COVID-19 Patients Conducted in Wuhan City. 2020 , Volume 12, 15-21	5
1911	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. 2020 , 2, 100169	68
1910	COVID-19 pandemic and the tension between the need to act and the need to know. 2020 , 50, 904-909	4
1909	[COVID-19: epidemiology and clinical facts]. 2020 , 60, 893-898	1
1908	An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. 2020 , 108, 333-336	1
1907	Pharmacogenomics of COVID-19 therapies. 2020 , 5, 35	36
1906	Probiotics and Coronavirus disease 2019: think about the link. 2021 , 126, 1564-1570	10
1905	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. 2020 , 18, 17	13
1904	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. 2020 , 12,	32
1903	Artificial intelligence, drug repurposing and peer review. 2020 , 38, 1127-1131	35
1902	Computational insight of dexamethasone against potential targets of SARS-CoV-2. 2020 , 1-11	11
1901	How to Be Fair, and Power Research? Select Patients by Flipping a Coin. 2020 , 20, 29-31	1
1900	Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems. 2020 , 13, 1095-1101	7

1899	Lessons Learned From the Front Line: Outcomes of Noninvasive Ventilation for Coronavirus Disease 2019 Pneumonia in China. 2020 , 48, 1400-1402	1
1898	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. 2020 , 13, 1071-1076	22
1897	Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection. 2020 , 9, CD013626	15
1896	Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them. 2020 , 9, CD013627	21
1895	. 2020 , 162, 62	
1894	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. 2020 , 9, 701-705	12
1893	COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review. 2020 , 125, 912-925	15
1892	Analysis and prediction of the COVID-19 outbreak in Pakistan. 2020 , 14, 730-747	2
1891	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. 2020 , 11, 572870	50
1890	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. 2020 , 7, 3464	9
1889	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. 2020 , 72, 2313-2330	7
1888	Implications of COVID-19 for an ageing population. 2020 , 213, 342-344.e1	14
1887	Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. 2020 , 9, 8571-8578	28
1886	How to Survive COVID-19 Even If the Vaccine Fails. 2020 , 4, 1864-1879	1
1885	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. 2020 , 83, 1704-1716	31
1884	Remdesivir, a remedy or a ripple in severe COVID-19?. 2020 , 29, 1195-1198	8
1883	Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. 2020 , 26, 1076029620955240	
1882	[COVID-19 infection-update]. 2020 , 25, 1-8	

1881	Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M. 2020 , 60, 5080-5102	38
1880	Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa. 2020 , 18, 690-704	23
1879	Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19. 2020 , 202, 1304-1308	25
1878	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. 2020 , 26, 1076029620945398	3
1877	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. 2020 , 11, 1205	68
1876	The efficacy of colchicine in the management of coronavirus disease 2019: A protocol for systematic review and meta-analysis. 2020 , 99, e21911	7
1875	The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). 2020 , 21,	16
1874	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131	2
1873	Marburg virus disease: A summary for clinicians. 2020 , 99, 233-242	8
1872	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. 2020 , 2, e0178	25
1871	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial. 2020 , 24, 502	26
1870	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
1869	Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. 2020 , 40, 597-601	6
1868	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. 2020 , 11, 656	24
1867	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. 2020 , 75, 3366-3372	56
1866	Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis. 2020 , 50, e13383	12
1865	Treatment Options for COVID-19: A Review. 2020 , 7, 480	46
1864	Antitussive nescapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. 2020 , 1-16	14

1863	Natural killer cell immunotypes related to COVID-19 disease severity. 2020 , 5,	183
1862	A concern about survival time as an endpoint in coronavirus disease 2019 clinical trials. 2020 , 17, 505-506	1
1861	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. 2020 , 8,	10
1860	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. 2020 , 324, 1048-1057	629
1859	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. 2020 , 25,	15
1858	Web Exclusive. Annals for Hospitalists Inpatient Notes - Remdesivir-Making Sense of Emerging Evidence. 2020 , 173, HO2-HO3	
1857	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. 2021 , 74, 1088-1100	22
1856	Development of vaccines and antivirals for combating viral pandemics. 2020 , 4, 1128-1133	27
1855	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. 2020 , 10, 21775	33
1854	Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. 2020 , 9,	8
1853	Innate lymphoid cell composition associates with COVID-19 disease severity. 2020 , 9, e1224	24
1852	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. 2020 , 20, 538	17
1851	Coronavirus vaccine development: from SARS and MERS to COVID-19. 2020 , 27, 104	133
1850	Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies. 2020 , 7, 589060	4
1849	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. 2020 , 11, 584956	30
1848	Rationale for COVID-19 Treatment by Nebulized Interferon- β -Literature Review and Personal Preliminary Experience. 2020 , 11, 592543	5
1847	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. 2020 , 17,	24
1846	Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery. 2020 , 40, 578-588	12

1845	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. 2020 , 33, 177-189	0
1844	Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. 2020 , 10, 589505	43
1843	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. 2020 , 7, 568720	5
1842	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. 2020 , 11, 569760	12
1841	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. 2020 , 7, 596587	7
1840	COVID-19 Induced Acute Respiratory Distress Syndrome-A Multicenter Observational Study. 2020 , 7, 599533	7
1839	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. 2020 , 7, 616341	38
1838	A New Crystal Form of the SARS-CoV-2 Receptor Binding Domain: CR3022 Complex-An Ideal Target for In-Crystal Fragment Screening of the ACE2 Binding Site Surface. 2020 , 11, 615211	3
1837	Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-Inflammation. 2020 , 11, 615398	18
1836	COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?. 2020 , 56,	3
1835	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. 2020 , 8,	30
1834	Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care. 2020 , 8, 2050312120974174	3
1833	Update on COVID-19 Myocarditis. 2020 , 56,	18
1832	Biocatalysis in the Swiss Manufacturing Environment. 2020 , 10, 1420	5
1831	Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. 2020 , 6, 96	50
1830	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. 2020 , 5,	134
1829	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. 2020 , 8, 590263	12
1828	Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. 2020 , 11, 596631	30

1827	Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial. 2020 , 41, 4387-4388	6
1826	Editorial from the new editor-in-chief. 2020 , 96, 106127	
1825	Remdesivir versus ritonavir/lopinavir in COVID-19 patients. 2021 , 190, 1249-1250	26
1824	Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. 2020 , 60, 5832-5852	71
1823	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. 2020 ,	2
1822	La FDA approuve le remdesivir comme traitement de la Covid-19. 2020 , 2020, 5	
1821	Enhancement of the IFN- γ -induced host signature informs repurposed drugs for COVID-19. 2020 , 6, e05646	7
1820	How chemical engineers can contribute to fight the COVID-19. 2020 , 116, 67-80	1
1819	Repurposing INCI-registered compounds as skin prebiotics for probiotic <i>Staphylococcus epidermidis</i> against UV-B. 2020 , 10, 21585	4
1818	SARS-CoV-2 receptor ACE2 is co-expressed with genes related to transmembrane serine proteases, viral entry, immunity and cellular stress. 2020 , 10, 21415	14
1817	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. 2021 , 19, 877-888	59
1816	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019. 2020 , 2, e0280	20
1815	Covid-19: EU countries spent over €20m stockpiling remdesivir despite lack of effectiveness, finds investigation. 2020 , 371, m4749	0
1814	Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. 2020 , 10, e041295	17
1813	Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome. 2020 , 2020, 8829309	3
1812	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. 2020 , 21, 1005	10
1811	Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey. 2020 , 6, 28	8
1810	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. 2020 , 11, 572168	8

1809	Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19. 2020 , 10,	5
1808	Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. 2021 , 12, 717-733	33
1807	Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19. 2020 , 22, 28115-28122	18
1806	Protocol for a prospective, longitudinal cohort of people with COVID-19 and their household members to study factors associated with disease severity: the Predi-COVID study. 2020 , 10, e041834	5
1805	COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment. 2020 , 13, 4953-4959	6
1804	Osmotic Adaptation by Na-Dependent Transporters and ACE2: Correlation with Hemostatic Crisis in COVID-19. 2020 , 8,	6
1803	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
1802	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. 2020 , 21, 841-844	3
1801	The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation. 2020 , 11, 590870	11
1800	Timing of Intubation and In-Hospital Mortality in Patients With Coronavirus Disease 2019. 2020 , 2, e0254	27
1799	Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?. 2020 , 16, 2123-2127	16
1798	Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. 2020 , 13,	3
1797	Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review. 2020 , 2, 2260-2264	42
1796	Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation. 2020 , 1-18	9
1795	COVID-19 and liver disease: An update. 2020 , 43, 472-480	1
1794	A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. 2020 , 86, 104610	13
1793	Racial Disproportionality in Covid Clinical Trials. <i>New England Journal of Medicine</i> , 2020 , 383, 2486-2487 59.2	13
1792	Severe SARS-CoV-2 Infection in a Pediatric Patient Requiring Extracorporeal Membrane Oxygenation. 2020 , 2020, 8885022	5

1791	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. 2020 , 11, 588654	41
1790	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11
1789	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. 2020 , 65,	29
1788	The role of the allergist/immunologist in the COVID-19 pandemic: A Janus-faced presentation. 2020 , 41, 397-412	7
1787	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. 2020 , 80, 1961-1972	13
1786	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. 2020 , 190, 346-357	8
1785	Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. 2020 , 24, 940-976	48
1784	A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals. 2020 , 324, 455-457	70
1783	Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. 2020 , 108, 425-427	4
1782	Severe Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2451-2460	59.2 613
1781	Covid-19: Selected NHS patients will be treated with remdesivir. 2020 , 369, m2097	11
1780	Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. 2020 , 143, 109851	31
1779	Remdesivir - An Important First Step. <i>New England Journal of Medicine</i> , 2020 , 383, 1886-1887	59.2 22
1778	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 1827-1837	59.2 778
1777	COVID-19 remedies. 2020 , 4, 575-576	
1776	Consideration of Pannexin 1 channels in COVID-19 pathology and treatment. 2020 , 319, L121-L125	14
1775	Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma. 2020 , 415, 116972	2
1774	Covid-19: a comprehensive review of a formidable foe and the road ahead. 2020 , 14, 869-879	9

1773	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). 2020 , 12,	34
1772	Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. 2020 , 40, 843-856	71
1771	IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. 2020 , 34, 223-231	81
1770	Contraception and reproductive planning during the COVID-19 pandemic. 2020 , 13, 615-622	37
1769	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. 2020 , 75, 2503-2541	58
1768	Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?. 2020 , 20, 412	7
1767	Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. 2020 , 14, 809-814	68
1766	COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. 2020 , 55, 2354-2356	20
1765	Current Status of COVID-19 Therapies and Drug Repositioning Applications. 2020 , 23, 101303	54
1764	CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019. 2020 , 3, 140-142	1
1763	Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. 2020 , 24, 100418	113
1762	The National Institute of Allergy and Infectious Diseases Decision to Stop the Adaptive COVID-19 Trial: On Solid Ethical and Scientific Grounds. 2020 , 5, 645-647	6
1761	Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. 2020 , 11, 1361-1366	86
1760	Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic. 2020 , 146, 376-377	9
1759	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. 2020 , 17, 1144-1153	13
1758	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. 2020 , 9, 1397-1406	31
1757	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. 2020 , 29, 973-987	68
1756	Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. 2020 , 109, 154282	33

1755	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. 2020 , 11, 1606	27
1754	Remdesivir investigational trials in COVID-19: a critical reappraisal. 2020 , 100707	3
1753	Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. 2020 , 9, e017111	4
1752	Dissecting the interaction between COVID-19 and diabetes mellitus. 2020 , 11, 1104-1114	22
1751	Novel insights on the pulmonary vascular consequences of COVID-19. 2020 , 319, L277-L288	69
1750	Use of convalescent plasma in hospitalized patients with COVID-19: case series. 2020 , 136, 759-762	100
1749	Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic. 2020 , 95, 1946-1954	10
1748	COVID-19: Some clinical questions after the first 4 months. 2020 , 50, e13326	3
1747	Oral Methioninase for Covid-19 Methionine-restriction Therapy. 2020 , 34, 1593-1596	5
1746	Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?. 2020 , 51, 741-742	30
1745	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. 2020 , 63, 682-689	126
1744	COVID-19: from epidemiology to treatment. 2020 , 41, 2092-2112	45
1743	The Prevention and Management of COVID-19: Seeking a Practical and Timely Solution. 2020 , 17,	8
1742	Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. 2020 , 12,	96
1741	Computer-generated "synthetic contingency" plans at times of logistics and supply problems: scenarios for hydroxychloroquine and remdesivir. 2020 , 11, 6736-6744	6
1740	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. <i>New England Journal of Medicine</i> , 2020 , 382, 2354-2364	59.2 9
1739	Azithromycin for COVID-19: More Than Just an Antimicrobial?. 2020 , 40, 683-686	54
1738	A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. 2020 , 125, 170-178	18

1737	Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166. 2020 , 202, 105719	72
1736	Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). 2020 , 11, 1451	184
1735	COVID-19 Diagnostics, Tools, and Prevention. 2020 , 10,	40
1734	Pirfenidone: A novel hypothetical treatment for COVID-19. 2020 , 144, 110005	30
1733	The cytokine storm of COVID-19: a spotlight on prevention and protection. 2020 , 24, 723-730	55
1732	Emerging pharmacotherapy for COVID-19. 2020 , 50, 133-137	3
1731	Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency. 2020 , 369, m2610	12
1730	Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. 2020 , 151, 197-202	20
1729	GS-5734: a potentially approved drug by FDA against SARS-Cov-2. 2020 , 44, 12417-12429	9
1728	[Remdesivir for patients with COVID-19]. 2020 , 61, 869-872	1
1727	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. 2020 , 6, 1028-1031	5
1726	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. 2020 , 64,	26
1725	COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot. 2020 , 202, 635-637	7
1724	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. 2020 , 9,	29
1723	Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review. 2020 , 12,	27
1722	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. 2020 , 32, 107940	260
1721	Pandemic COVID-19: Current status and challenges of antiviral therapies. 2020 , 7, 502-519	7
1720	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. 2020 , 8, 355	20

1719	BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?. 2020 , 11, 516	39
1718	Is hydroxychloroquine beneficial for COVID-19 patients?. 2020 , 11, 512	57
1717	Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. 2020 , 324, 782-793	1978
1716	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. 2020 , 7, CD013600	100
1715	Commercial influence and covid-19. 2020 , 369, m2456	9
1714	Metabolomics to Predict Antiviral Drug Efficacy in COVID-19. 2020 , 63, 396-398	30
1713	Pharmacotherapeutics Advice in Guidelines for COVID-19. 2020 , 11, 950	6
1712	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. 2020 , 36, 101791	162
1711	Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". 2020 , 26, e241-e242	1
1710	Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. 2020 , 13, 896-906	95
1709	Remdesivir for the Treatment of Covid-19 - Preliminary Report. <i>New England Journal of Medicine</i> , 2020 , 383, 992	59.2 167
1708	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. 2020 , 20, 3140-3148	165
1707	Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas. 2020 , 7, 817-821	6
1706	Dexamethasone in the management of covid -19. 2020 , 370, m2648	124
1705	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919	17
1704	Outbreak of COVID-19: An emerging global pandemic threat. 2020 , 129, 110499	22
1703	Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. 2020 , 20, 3019-3029	48
1702	Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. 2020 , 11,	35

1701	Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 1757-1766	59.2	627
1700	The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. 2021 , 72, 1642-1644		9
1699	Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. 2021 , 72, 1256-1258		34
1698	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. 2021 , 72, 1067-1073		2
1697	Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation. 2021 , 128, 104102		16
1696	Potential role of interferons in treating COVID-19 patients. 2021 , 90, 107171		36
1695	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59		1
1694	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. 2021 , 203, 24-36		127
1693	SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. 2020 , 350, 577436		49
1692	Risk, Results, and Costs: Optimizing Clinical Trial Efficiency through Prognostic Enrichment. 2021 , 203, 671-672		1
1691	The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. 2021 , 29, 91-100		100
1690	Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. 2021 , 44, 43-53		16
1689	Supports for people with intellectual and developmental disabilities during the COVID-19 pandemic from their own perspective. 2021 , 108, 103813		27
1688	Treating COVID-19: are we missing out the window of opportunity?. 2021 , 76, 283-285		9
1687	Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. 2021 , 72, e373-e381		198
1686	SARS-CoV-2 and the pandemic of COVID-19. 2021 , 97, 110-116		61
1685	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a ´real-life patient cohort. 2021 , 133, 284-291		22
1684	Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. 2021 , 180, 307-322		124

1683	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. 2021 , 19, 5-16		15
1682	Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. 2021 , 93, 1403-1408		44
1681	Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis. 2021 , 73, 1521-1530		18
1680	Research in the Context of a Pandemic. <i>New England Journal of Medicine</i> , 2021 , 384, 755-757	59.2	34
1679	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 693-704	59.2	4434
1678	[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. 2021 , 45, 104-121		8
1677	Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome. 2021 , 23, 107-113		78
1676	Surging publications on the COVID-19 pandemic. 2021 , 27, 484-486		1
1675	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862		10
1674	Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. 2021 , 80, 153337		47
1673	Characteristics of SARS-CoV-2 and COVID-19. 2021 , 19, 141-154		1287
1672	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study. 2021 , 72, e466-e475		13
1671	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. 2021 , 44, 13-34		59
1670	Operational Recommendations for Scarce Resource Allocation in a Public Health Crisis. 2021 , 159, 1076-1083		7
1669	Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and Entry. 2021 , 7, 1423-1432		8
1668	A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. 2021 , 43, 324-328		23
1667	SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?. 2021 , 1486, 15-38		35
1666	COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. 2021 , 97, 312-320		172

1665	Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. 2021 , 22, 939-948	21
1664	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. 2021 , 181, 32-40	407
1663	Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. 2021 , 51, 657-662	25
1662	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. 2021 , 181, 41-51	213
1661	[Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm : Perimyocarditis and coagulopathy after administration of tocilizumab]. 2021 , 70, 121-126	4
1660	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. 2021 , 40, 761-769	21
1659	Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study. 2021 , 16, 883-893	8
1658	Pathogenesis-directed therapy of 2019 novel coronavirus disease. 2021 , 93, 1320-1342	22
1657	Cardiac Involvement of COVID-19: A Comprehensive Review. 2021 , 361, 14-22	40
1656	Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. 2021 , 17, 1113-1121	4
1655	Treatment of immunocompromised COVID-19 patients with convalescent plasma. 2021 , 23, e13477	22
1654	Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. 2021 , 31, 217-220	11
1653	Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. 2021 , 6, 206-210	42
1652	Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. 2021 , 76, 286-291	16
1651	Review on therapeutic targets for COVID-19: insights from cytokine storm. 2021 , 97, 391-398	11
1650	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. 2021 , 41, 303-314	27
1649	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. 2021 , 183, 114296	44
1648	Mechanism of inhibition of SARS-CoV-2 M by peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. 2020 , 12, 1433-1444	50

1647	Off-Target Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. 2021 , 65,	17
1646	The COVID-19 pandemic: consequences for nephrology. 2021 , 17, 81-82	28
1645	Review of registered clinical trials for the treatment of COVID-19. 2021 , 82, 474-493	14
1644	Repurposing medications. 2021 , 19, 336-340	4
1643	One year update on the COVID-19 pandemic: Where are we now?. 2021 , 214, 105778	70
1642	Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19. 2021 , 221, 107745	4
1641	Nucleic Acid-Based Technologies Targeting Coronaviruses. 2021 , 46, 351-365	17
1640	Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021 , 384, 497-511	59.2 1158
1639	Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. 2021 , 2, e34-e41	83
1638	A Large, Simple Trial Leading to Complex Questions. <i>New England Journal of Medicine</i> , 2021 , 384, 576-577	59.2 15
1637	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. 2021 , 14, 95-103	30
1636	Immunity and inflammatory biomarkers in COVID-19: A systematic review. 2021 , 31, e2199	13
1635	SARS-CoV-2 and the COVID-19 pandemic. 2021 , 445-467	1
1634	Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. 2021 , 133, 111064	18
1633	SARS-CoV-2: Targeted managements and vaccine development. 2021 , 58, 16-29	21
1632	Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. 2021 , 63, 103154	53
1631	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. 2021 , 55, 1-11	19
1630	Public perceptions about pharmacists' role in prescribing, providing education and delivering medications during COVID-19 pandemic era. 2021 , 75, e13890	7

1629	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426	11
1628	Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?. 2021 , 146, 110452	13
1627	Immunopathogenesis and treatment of cytokine storm in COVID-19. 2021 , 11, 316-329	118
1626	Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). 2021 , 174, 229-236	2
1625	From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19. 2021 , 326, 243-247	8
1624	High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2. 2021 , 7, 1409-1422	12
1623	Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis. 2021 , 76, 822-825	11
1622	Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. 2021 , 128, 204-212	53
1621	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488	14
1620	Management of COVID-19 from the pulmonologist's perspective: a narrative review. 2021 , 15, 519-535	7
1619	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891	1
1618	Pharmacokinetics under the COVID-19 storm. 2020 ,	3
1617	Probiotics in the prophylaxis of COVID-19: something is better than nothing. 2021 , 11, 1	29
1616	The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. 2021 , 128, 621-624	13
1615	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. 2021 , 11, 731-753	28
1614	The place for remdesivir in COVID-19 treatment. 2021 , 21, 20-21	52
1613	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. <i>New England Journal of Medicine</i> , 2021 , 384, 619-629	59.2 462
1612	Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID-19: results from a retrospective cohort study. 2021 , 37, 543-548	10

1611	A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. 2021 , 65,	15
1610	Imaging algorithm for COVID-19: A practical approach. 2021 , 72, 22-30	7
1609	Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. 2021 , 130, 107-116	9
1608	Compassionate use of remdesivir in children with COVID-19. 2021 , 180, 1317-1322	16
1607	Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. 2021 , 18, 194-209	141
1606	COVID-19: A review of therapeutic strategies and vaccine candidates. 2021 , 222, 108634	109
1605	COVID-19-Associated Glomerular Disease. 2021 , 32, 33-40	69
1604	COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. 2021 , 109, 688-696	20
1603	Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. 2021 , 146, 110394	20
1602	Food-derived antioxidants and COVID-19. 2021 , 45, e13557	26
1601	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. 2021 , 9, 196-206	219
1600	Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. 2021 , 174, 33-41	82
1599	Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points. 2021 , 174, 209-220	36
1598	Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research. 2021 , 174, 256-257	2
1597	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. 2021 , 17, 11-30	293
1596	Coronavirus disease 2019 vaccines in pregnancy. 2021 , 3, 100295	20
1595	Zoonotic coronavirus epidemics: Severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019. 2021 , 126, 321-337	6
1594	Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection and in a mouse model expressing human ACE2. 2021 , 66, 925-936	11

1593	Recent Insights into Emerging Coronavirus: SARS-CoV-2. 2021 , 7, 1369-1388		13
1592	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 795-807	59.2	712
1591	Repurposing drugs for the management of COVID-19. 2021 , 31, 295-307		23
1590	Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. 2021 , 15, 301-324		12
1589	Risk and Management of Venous Thromboembolism in Patients with COVID-19. 2021 , 73, 78-85		3
1588	The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. 2021 , 538, 80-87		10
1587	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. 2021 , 20, 25-30		22
1586	Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails. 2021 , 16, 385-397		13
1585	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. 2021 , 29, 873-885		29
1584	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. 2021 , 4, 206-212		12
1583	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. 2021 , 23, 886-896		19
1582	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102		7
1581	Compiling Observational Research During a Pandemic: A Necessary Bridge. 2021 , 72, e750-e752		1
1580	A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. 2021 , 8, ofaa617		1
1579	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. 2021 , 80, 660-666		37
1578	Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives. 2021 , 76, 196-200		11
1577	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. 2021 , 26, 311-329		0
1576	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. 2020 , 7, 585899		6

1575	Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance. 2021 , 6, 586-593	32
1574	Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. 2021 , 76, 825-827	19
1573	Antibiotic usage and stewardship in patients with COVID-19: too much antibiotic in uncharted waters?. 2021 , 22, 119-125	6
1572	Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians. 2021 , 37, 62-74	3
1571	Selective Pressure-Free Treatments for COVID-19. 2021 , 1, 18-32	2
1570	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231	17
1569	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 905-914	59.2 203
1568	Can drug repurposing strategies be the solution to the COVID-19 crisis?. 2021 , 16, 605-612	10
1567	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. 2021 , 76, 753-757	25
1566	Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy. 2021 , 58, 114-133	11
1565	Remdesivir: From Ebola to COVID-19. 2021 , 538, 145-150	18
1564	COVID-19 in Brazil: 150,000 deaths and the Brazilian underreporting. 2021 , 99, 115258	18
1563	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. 2021 , 57, 106222	13
1562	Compartmental immunophenotyping in COVID-19 ARDS: A case series. 2021 , 147, 81-91	33
1561	Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cell-Derived Intestinal Organoids. 2021 , 11, 935-948	33
1560	A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful. 2021 , 27, 379-383	2
1559	Critically ill patients with COVID-19 in Tokyo, Japan: A single-center case series. 2021 , 27, 291-295	3
1558	Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR. 2021 , 100, 106473	2

1557	KG-COVID-19: A Framework to Produce Customized Knowledge Graphs for COVID-19 Response. 2021 , 2, 100155	24
1556	Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies. 2021 , 56, 90-93	
1555	Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia. 2021 , 59, 187-193	15
1554	The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium. 2021 , 2, 100019	18
1553	Impact of COVID-19 in solid organ transplant recipients. 2021 , 21, 925-937	37
1552	Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. 2020 , 11, 592908	27
1551	Biomarkers for the clinical development of antiviral therapies. 2021 , 100, 19-32	
1550	The safety of remdesivir for COVID-19 patients. 2021 , 93, 1910-1912	9
1549	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. 2021 , 10, 89-99	12
1548	COVID-19 pandemic in Japan. 2021 , 41, 1-5	19
1547	COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic Management of 2019 Novel Coronavirus Disease. 2021 , 44, 128-137	10
1546	SARS-CoV-2 persistence and non-protective immunity in infected haematological patients. 2021 , 192, e51-e54	2
1545	Palliative care for cancer patients with severe COVID-19: the challenge of uncertainty. 2021 , 29, 1153-1155	10
1544	Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. 2021 , 184, 92-105.e16	240
1543	A Comprehensive Review of Neurologic Manifestations of COVID-19 and Management of Pre-existing Neurologic Disorders in Children. 2021 , 36, 324-330	8
1542	Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials. 2021 , 93, 1860-1861	7
1541	Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. 2021 , 71, 138-148	3
1540	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. 2021 , 87, 2170-2185	7

1539	Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis. 2021 , 203, 54-66	106
1538	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. 2021 , 54, 27-36	8
1537	Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies. 2021 , 72, e887-e889	2
1536	Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. 2021 , 38, 782-791	8
1535	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 229-237	59.2 717
1534	Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. 2020 , 4, 2000172	14
1533	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
1532	Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. 2021 , 264, 118663	21
1531	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. 2021 , 96, 183-202	30
1530	Ostracizing Children from Research in COVID-19: Is it Ethical?. 2021 , 88, 305-306	
1529	Case report: a fatal combination of hemophagocytic lymphohistiocytosis with extensive pulmonary microvascular damage in COVID-19 pneumonia. 2020 , 14, 1-5	6
1528	DGI recommendations for COVID-19 pharmacotherapy. 2021 , 49, 369-370	1
1527	Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries. 2020 , 37, 1-3	2
1526	Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. 2021 , 102, 303-309	4
1525	Union is strength: antiviral and anti-inflammatory drugs for COVID-19. 2021 , 26, 229-239	15
1524	SARS-CoV-2 and COVID-19 for the ophthalmologist. 2021 , 49, 70-80	1
1523	Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease. 2021 , 33, e64-e68	1
1522	Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. 2021 , 77, 141-144	1

1521	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. 2021 , 35, 1121-1133	35
1520	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. 2021 , 72, e558-e565	61
1519	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. 2021 , 87, 845-857	3
1518	The role of dedicated biocontainment patient care units in preparing for COVID-19 and other infectious disease outbreaks. 2021 , 42, 208-211	7
1517	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. 2021 , 11, 45-52	22
1516	Azithromycin in viral infections. 2021 , 31, e2163	36
1515	Pregnancy and COVID-19: pharmacologic considerations. 2021 , 57, 195-203	23
1514	Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view. 2021 , 97, 140-159	19
1513	Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. 2021 , 51, 649-656	8
1512	The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. 2021 , 73, 23-35	27
1511	Susceptibility to COVID-19 in populations with health disparities: Posited involvement of mitochondrial disorder, socioeconomic stress, and pollutants. 2021 , 35, e22626	6
1510	Emergency Use Authorization for Remdesivir and Its Potential Implications. 2021 , 55, 270-271	2
1509	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. 2021 , 10, 34-48	37
1508	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects.. 2021 , 31, e2168	14
1507	Methylprednisolone for Coronavirus Disease 2019 (COVID-19): Was Benjamin Rush Prescient?. 2021 , 72, e382-e383	1
1506	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71
1505	Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach. 2021 , 72, 1843-1849	8
1504	COVID-19 in patients with cirrhosis: understanding adverse impact. 2021 , 70, 1409	1

1503	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287	11
1502	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). 2021 , 27, 244-252	61
1501	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. 2021 , 41, 5-28	43
1500	Declining Intensive Care Unit Mortality of COVID-19: A Multi-Center Study. 2021 , 13, 184-190	4
1499	Lines of Treatment of COVID-19 Infection. 2021 , 91-144	1
1498	Exploration of FDA-approved drug interactions with SARS-CoV2 main protease using structure-based virtual screening and MM-GBSA binding free energy methods. 2021 ,	
1497	"Kit-covid" and the Popular Pharmacy Program in Brazil. 2021 , 37, e00348020	0
1496	Enfermedad causada por COVID-19. 2021 , 44, 70-72	1
1495	Legionella and SARS-CoV-2 Coinfection in a Patient With Pneumonia - An Outbreak in Northern Portugal. 2021 , 13, e12476	2
1494	COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. 2021 , 81, 46-60	2
1493	Current Directions in Research and Treatment of COVID-19. 2021 , 000, 000-000	
1492	Arrhythmias in the Age of Coronavirus Disease 2019. 2021 , 12, 4345-4348	
1491	Conundrum of COVID-19: The road ahead. 2021 , 12, 1	
1490	The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?. 2021 , 17, 1476-1485	11
1489	Shedding light on therapeutics in alopecia and their relevance to COVID-19. 2021 , 39, 76-83	3
1488	Experimental Models to Study COVID-19 Effect in Stem Cells. 2021 , 10,	7
1487	Management of COVID-19 in an adolescent demonstrates lasting effects of extreme prematurity on pulmonary function. 2021 , 33, 101394	
1486	Remdesivir in The Treatment of COVID-19. 2021 , 121, 55	1

1485	Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant. 2021 , 30, 47-53	0
1484	Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase.	1
1483	Dethroning the crown. From the kinetics and dynamics of COVID-19 diagnosis to promising treatments. 2021 , 349-357	
1482	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. 2021 , 379, 4	8
1481	A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients. 2021 , 16, e0245025	3
1480	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. 2021 , 1322, 219-260	1
1479	COVID-19 pneumonia with stroke: Is it a vascular phenomenon or thrombotic event?. 2021 , 2, 79	
1478	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. 2021 , 21, 3-9	4
1477	What is the value of community oximetry monitoring in people with SARS-CoV-2? A prospective, open-label clinical study.	2
1476	Active vitamin D supplementation and COVID-19 infections: review. 2021 , 190, 1271-1274	7
1475	COVID-19-neutralizing antibodies predict disease severity and survival. 2021 , 184, 476-488.e11	270
1474	In the interest of public safety: rapid response to the COVID-19 epidemic in Vietnam. 2021 , 6,	19
1473	Effect of early application of social distancing interventions on COVID-19 mortality over the first pandemic wave: An analysis of longitudinal data from 37 countries. 2021 , 82, 133-142	32
1472	QTc Prolongation in COVID-19 Patients Using Chloroquine. 2021 , 21, 314-321	2
1471	Safety in Endoscopy for Patients and Healthcare Workers During the COVID-19 Pandemic. 2021 , 23, 170-178	5
1470	Therapeutic targets and potential agents for the treatment of COVID-19. 2021 , 41, 1775-1797	11
1469	Remdesivir Approved to Treat COVID-19 Amid Controversy. 2021 , 121, 22-24	5
1468	Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. 2021 , 10, 291-304	29

1467	Current treatment in COVID-19 disease: a rapid review. 2021 , 10,	19
1466	Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. 2021 , 17, e1009292	32
1465	Pretest Symptom Duration and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain Reaction Predict Coronavirus Disease 2019 Mortality. 2021 , 8, ofab003	12
1464	In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. 2021 , 40, 296-309	28
1463	RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. 2021 , 1-13	10
1462	Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study. 2021 , 18, 921-928	6
1461	Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection. 2021 , 8, 16	10
1460	Acyclovir As a Potential Add-On Treatment for COVID-19; A Narrative Review.	1
1459	Knowledge-based Modeling of SARS-CoV-2 Proteins and Predicting its Potential Drugs. 2021 , 61, 102-106	
1458	Pharmacologic treatment of COVID-19: Evidence-based update. 2021 , 10, 34	0
1457	COVID-19: The battle of Maharashtra. 2021 , 69, 477-478	2
1456	Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication. 2021 , 4, 724-737	5
1455	A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection. 2021 , 12, 94-98	2
1454	A data science perspective of real-world COVID-19 databases. 2021 , 133-163	1
1453	A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects. 2021 , 15,	2
1452	Remdesivir in COVID-19 Patients with Impaired Renal Function. 2021 , 32, 518-519	1
1451	Blockchain and AI-Based Solutions to Combat Coronavirus (COVID-19)-Like Epidemics: A Survey. 2021 , 9, 95730-95753	35
1450	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. 2021 , 75, 88-112	14

1449	Current Evidence on Coronavirus Disease-2019: A Comprehensive Review. 2021 , 3, 65-73	1
1448	Dietary Supplements for COVID-19. 2021 , 1318, 499-515	2
1447	Remdesivir in a pregnant patient with COVID-19 pneumonia. 2021 , 11, 103-106	5
1446	Japanese Rapid/Living recommendations on drug management for COVID-19. 2021 , 8, e664	6
1445	Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. 2021 , 35, e14216	14
1444	Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. 2021 ,	22
1443	Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities invitro.	4
1442	Mortality Risk Assessment in COVID-19 Venovenous Extracorporeal Membrane Oxygenation. 2021 , 112, 1983-1989	9
1441	Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. 2021 , 2, 100045	4
1440	Genome-scale metabolic modeling reveals SARS-CoV-2-induced host metabolic reprogramming and identifies metabolic antiviral targets. 2021 ,	1
1439	Notes from the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient with Severe COVID-19 and Cytokine Release Syndrome (Preprint).	
1438	Applying the lessons learned from coronavirus disease 2019 to improve pneumonia management. 2021 , 34, 175-179	1
1437	In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response.	1
1436	Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries. 2021 , 49, 543-575	11
1435	Cardiovascular Health and Disease in the Context of COVID-19. 2021 , 12, 67-79	7
1434	The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial.	7
1433	COVID-19: An overview and a clinical update. 2021 , 9, 8-23	17
1432	Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. 2021 , 36, 147-153	14

1431	The role of chemical biology in the fight against SARS-CoV-2. 2021 , 478, 157-177	2
1430	Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?. 2021 , 190, 1637-1638	21
1429	Incorporation efficiency and inhibition mechanism of 2'-substituted nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase. 2021 , 23, 20117-20128	3
1428	Ivermectin as a potential treatment for mild to moderate COVID-19 [A double blind randomized placebo-controlled trial.	14
1427	In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches. 2021 , 26,	16
1426	Early mortality benefit with COVID-19 convalescent plasma: a matched control study. 2021 , 192, 706-713	31
1425	Clinical characteristics and outcome of novel coronavirus disease in kidney transplant recipients: A single-center prospective observational study. 2021 , 15, 189	
1424	Remdesivir induces persistent mitochondrial and structural damage in human induced pluripotent stem cell derived cardiomyocytes. 2021 ,	2
1423	NCATS Inxight Drugs: a comprehensive and curated portal for translational research. 2021 ,	3
1422	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. 2021 , 325, 254-264	157
1421	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. 2021 , 28, 9	52
1420	Probing remdesivir nucleotide analogue insertion to SARS-CoV-2 RNA dependent RNA polymerase in viral replication.	2
1419	The Development of a Novel Outpatient Infusion Therapy Center for Treatment of COVID-19 in a Rural Healthcare System. 2021 , 12, 21501327211007020	
1418	Public Health Emergencies. 2021 , 271-304	
1417	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. 2021 , 1-143	2
1416	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. 2021 ,	5
1415	structure-based discovery of a SARS-CoV-2 main protease inhibitor. 2021 , 17, 1555-1564	5
1414	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89	

1413	Model-based cellular kinetic analysis of SARS-CoV-2 infection: different immune response modes and treatment strategies.	0
1412	Management of COVID-19 infection in patients undergoing hemodialysis. 2021 , 38, 13	0
1411	The emergence of a new cytokine storm during the COVID-19 pandemic: Multisystem inflammatory syndrome in children. 2021 , 37, 255-256	1
1410	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. 2021 , 12, 593223	42
1409	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. 2021 , 11, e297	32
1408	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. 2021 , 32, 3-17	3
1407	Red Blood Cell Distribution Width, Disease Severity, and Mortality in Hospitalized Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. 2021 , 10,	5
1406	Hospital load and increased COVID-19 related mortality - a nationwide study in Israel.	1
1405	Effectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury. 2021 , 9, 67-71	
1404	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. 2021 , 75, 19-47	17
1403	Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis. 2021 , 21, 43-50	5
1402	Viral infections in lung transplantation.. 2021 , 13, 6673-6694	0
1401	Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. 2021 ,	5
1400	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. 2021 , 36, e83	10
1399	Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase. 2021 , 7, 164-174	11
1398	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. 2021 , 49, e219-e234	119
1397	Underpinning the Rudimentary/Underlying Mechanisms Involved in the Pathogenesis of SARS-CoV-2 (COVID-19) in Human Lung Cells. 2021 , 537-557	1
1396	Antiviral nanoparticle ligands identified with datamining and high-throughput virtual screening.. 2021 , 11, 23136-23143	1

1395	The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models.	3
1394	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. 2021 , 13,	7
1393	Elevated liver function tests in COVID-19: Causes, clinical evidence, and potential treatments. 2021 , 46, 21-26	7
1392	Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review. 2021 , 14, 13-56	19
1391	JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. 2021 , 21, 47	34
1390	The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells. 2021 , 12, 2214-2227	1
1389	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. 2021 , 1, 2000063	2
1388	Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design. 2021 , 12, 13492-13505	0
1387	Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. 2021 , 36, 1646-1650	22
1386	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.	11
1385	Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2.	1
1384	Realizing Public Rights Through Government Patent Use. 2021 , 49, 34-38	2
1383	A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients. 2021 , 53, 512-518	1
1382	Modulating the host immune response to fight against COVID-19: Where are we in 2021?. 2021 , 12, 1732-1736	5
1381	A Systematic Review of Systematic Reviews on the COVID-19 Pandemic. 2021 , 3, 1-18	22
1380	Severe Acute Respiratory Syndrome Coronavirus-2-Associated Acute Kidney Injury: A Narrative Review Focused Upon Pathophysiology. 2021 , 49, e533-e540	0
1379	Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients. 2021 , 8, ofab001	8
1378	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,	11

1377	Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. 2020 , 7, 606429	17
1376	Collaborative Response to COVID-19 Pandemic, and Development of Treatment Guidelines. 2021 , 53, 151-154	3
1375	Benign Synthesis of Fused-thiazoles with Enone-based Natural Products and Drugs for Lead Discovery. 2021 , 45, 6001-6017	1
1374	[COVID-19 and renal transplantation]. 2021 , 16, 1-8	0
1373	Clinical and Angiographic Features in Three COVID-19 Patients with Takotsubo Cardiomyopathy. Case Report. 2021 , 3, 1-6	2
1372	Shifting Coronavirus Disease 2019 Testing Policy and Research to Include the Full Translation Pipeline. 2021 , 8, ofaa649	1
1371	Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial. 2021 , 223, 1339-1344	
1370	From SARS and MERS to COVID-19: a review of the quality and responsiveness of clinical management guidelines in outbreak settings.	0
1369	Perioperative pain management in COVID-19 patients: Considerations and recommendations by the Saudi Anesthesia Society (SAS) and Saudi Society of Pain Medicine (SSPM). 2021 , 15, 59-69	0
1368	Coronavirus (COVID-19): A Systematic Review and Meta-analysis to Evaluate the Significance of Demographics and Comorbidities. 2021 ,	4
1367	Youden J and the Bi Error Method. 2021 , 196-209	
1366	Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing. 2021 , 77, 935-937	1
1365	Surviving and thriving in thrombosis research during a global pandemic: Experiences of a vascular scientist diagnosed with COVID-19. 2021 , 2, 100028	2
1364	[Cardiovascular diseases and COVID-19 : Pathophysiology, complications and treatment]. 2021 , 46, 107-114	0
1363	Perinatal Cells: A Promising COVID-19 Therapy?. 2020 , 8, 619980	2
1362	Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages. 2021 , 12, 2042098621998876	
1361	"Switching On" Enzyme Substrate Specificity Analysis with a Fluorescent Competitive Inhibitor. 2021 , 60, 440-450	
1360	Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. 2021 ,	5

1359	Catalogue of self-targeting nano-medical inventions to accelerate clinical trials. 2021 , 9, 3898-3910	0
1358	Cardiac Manifestations of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection. 2021 , In Press,	1
1357	HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German 'hotspot'. 2021 , 49, 313-320	3
1356	Similarities and differences between HIV and SARS-CoV-2. 2021 , 18, 846-851	7
1355	In silico dynamics of COVID-19 phenotypes for optimizing clinical management. 2021 , 118,	14
1354	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. 2021 , 71, 342-358	0
1353	The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. 2021 , 104, 35-38	13
1352	SARS-CoV-2: Outline, Prevention, and Decontamination. 2021 , 10,	8
1351	Principles of Pharmacological Therapy. 2021 , 155-169	
1350	A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report. 2021 , 28, 248-253	10
1349	Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. 2021 , 53, 391-401	16
1348	COVID-19 Infection in Renal Transplant Patients: Early Report From India. 2021 , 31, 271-275	1
1347	[Prevalence of SARS-CoV-2 in employees of a general hospital in Northrhine-Westphalia, Germany]. 2021 , 146, e30-e38	3
1346	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. 2021 , 93, 2694-2704	9
1345	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. 2021 , 49, 401-410	26
1344	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,	28
1343	The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 2021 , 17, e1008470	7
1342	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. 2020 , 11, 605908	37

1341	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. 2021 , 23, 14	93
1340	Therapeutic Development in COVID-19. 2021 , 1318, 435-448	1
1339	Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. 2021 , 6,	22
1338	A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. 2021 , 12, 668	55
1337	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. 2020 , 11, 571416	126
1336	Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. 2021 , 65, S41-S46	24
1335	Worsening of heart failure by coronavirus disease 2019 is associated with high mortality. 2021 , 8, 943-952	7
1334	Pharmacists knowledge and contribution during coronavirus disease-2019 pandemic in Sudan, 2020. 2021 , 5, 31	
1333	Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective. 2021 , 38, 382-386	1
1332	Reflections on a Year of SARS-CoV-2. 2021 , 7, 3-5	
1331	Treatment Strategies for COVID-19 in Pregnancy: Short Review of Current Recommendations. 2021 , 11, 823-829	1
1330	The COVID-19 Infodemic (Preprint).	
1329	Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. 2021 , 23, 179-189	9
1328	A review on the advancements in the development of vaccines to combat coronavirus disease 2019. 2021 , 10, 6-12	7
1327	COVID-19 in Qatar: Ways forward in public health and treatment. 2020 , 2020, 38	0
1326	Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects. 2021 , 14, 1039-1041	2
1325	Race and ethnicity do not impact eligibility for remdesivir- a single-center experience.	
1324	The changing characteristics of COVID-19 presentations: A regional comparison of SARS-CoV-2 hospitalised patients during the first and second wave.	1

1323	A rigorous evaluation of optimal peptide targets for MS-based clinical diagnostics of Coronavirus Disease 2019 (COVID-19). 2021,	
1322	MOATAI-VIR - an AI algorithm that predicts severe adverse events and molecular features for COVID-19 complications.	
1321	Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequelae. 2021, 16, e0246803	16
1320	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. 2020, 11, 630500	15
1319	Colchicine use in patients with COVID-19: a systematic review and meta-analysis.	6
1318	Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19. 2021, 22,	14
1317	Therapeutic Strategies in the Management of COVID-19. 2020, 7, 636738	8
1316	Getting Real: The Maryland Healthcare Ethics Committee Network's COVID-19 Working Group Debriefs Lessons Learned. 2021, 33, 91-107	0
1315	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021, 23, 5	8
1314	Targeted Drug Repurposing Against the SARS-CoV-2 E channel Identifies Blockers With in vitro Antiviral Activity.	1
1313	Coronavirus disease 2019 management. 2021, 27, 169-175	1
1312	An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. 2021, 8, 630209	6
1311	Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia. 2021, 41, 926-929	4
1310	COVID-19 and Its Implications for Thrombosis and Anticoagulation. 2021, 42, 316-326	7
1309	Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. 2021, 101, 106514	2
1308	SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. 2021, 93, 3047-3054	5
1307	Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease. 2020, 8, 624163	7
1306	The SARS-CoV-2-Inactivating Activity of Hydroxytyrosol-Rich Aqueous Olive Pulp Extract (HIDROX) and Its Use as a Virucidal Cream for Topical Application. 2021, 13,	12

1305	The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. 2021 , 25, 85-101	4
1304	Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. 2021 , 3, e131-e137	27
1303	Methodological quality of COVID-19 clinical research. 2021 , 12, 943	30
1302	Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape. 2021 , 18, 324-334	3
1301	Atteintes pulmonaires liées à la COVID-19. 2021 , 2, 14-24	0
1300	Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial.	8
1299	Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19. 2021 , 4, 1-25	35
1298	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. 2021 , 371,	1183
1297	Four Cases of Coronavirus Disease 2019 Transferred from a Cruise Ship. 2021 , 60, 479-485	
1296	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914	4
1295	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. 2021 , 7, e22483	0
1294	Just the facts: updates in COVID-19 therapeutics. 2021 , 23, 283-285	
1293	Zulassungsstudie für Remdesivir zur Therapie von COVID-19 voll publiziert. 2021 , 75, 86-86	
1292	Characteristics, Treatment, and Outcomes of Patients With Severe or Life-threatening COVID-19 at a Military Treatment Facility-A Descriptive Cohort Study. 2021 ,	0
1291	Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis.	
1290	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. 2021 , 24, 102021	18
1289	A Modelling Framework for Embedding-based Predictions for Compound-Viral Protein Activity. 2021 ,	3
1288	Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities. 2021 , 21, 42	4

1287	Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. 2021 , 62, 43-48	14
1286	Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. 2021 , 8, 628144	18
1285	Pediatric Coronavirus Disease 2019: Clinical Features and Management. 2021 , 58, 453-460	3
1284	COVID-19: Molecular and Cellular Response. 2021 , 11, 563085	10
1283	Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19. 2021 , 41, 221-233	23
1282	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. 2021 , 18, 105-118	2
1281	Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. 2021 , 2, 100080	20
1280	Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. 2021 , 76, 970-979	80
1279	2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus. 2021 ,	7
1278	Remdesivir for COVID-19 in Europe: will it provide value for money?. 2021 , 9, 127-128	8
1277	A single-cell and spatial atlas of autopsy tissues reveals pathology and cellular targets of SARS-CoV-2. 2021 ,	15
1276	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. 2021 , 101, 106272	30
1275	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. 2021 , 35, e21409	27
1274	Intensive care management of patients with COVID-19: a practical approach. 2021 , 11, 36	28
1273	Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review. 2021 , 8,	18
1272	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. 2021 , 325, 632-644	443
1271	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. 2021 ,	5
1270	Time to remind us that absence of evidence is not evidence of absence during the coronavirus disease 2019 (COVID-19) pandemic. 2021 , 1	

1269	AKI in Hospitalized Patients with COVID-19 and Seasonal Influenza: A Comparative Analysis.. 2021 , 2, 619-628	1
1268	Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.	3
1267	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.	
1266	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. 2021 , 16, 165-183	
1265	The basic reproduction number can be accurately estimated within 14 days after societal lockdown: The early stage of the COVID-19 epidemic in Denmark. 2021 , 16, e0247021	2
1264	Outcomes of COVID-19 among Patients with End Stage Renal Disease on Remdesivir.	1
1263	Results of an early second PCR test performed on SARS-CoV-2 positive patients may indicate risk for severe COVID-19.	
1262	Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. 2021 , 78, 568-577	2
1261	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. 2021 , 10, 1945	2
1260	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. 2021 , 8, 604087	
1259	Ensuring continued progress for development of COVID-19 therapeutics in children. 2021 ,	
1258	Update in Viral Infections in the Intensive Care Unit. 2021 , 8, 575580	3
1257	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. 2021 , 9, 74-87	
1256	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2021 , 2, CD013587	57
1255	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). 2021 , 22, 1127-1141	3
1254	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitely Get a Role to ?. 2021 , 11, 625581	19
1253	Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics. 1-17	3
1252	Early remdesivir treatment in COVID-19: Why wait another day?. 2021 , 93, 4078-4080	2

1251	Less Severe Cases of COVID-19 in Sub-Saharan Africa: Could Co-infection or a Recent History of Infection Be Protective?. 2021 , 12, 565625	6
1250	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. 2020 , 11, 616595	8
1249	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. 2021 , 25, 1905-1927	8
1248	COVID-19-associated liver injury: from bedside to bench. 2021 , 56, 218-230	16
1247	SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination.	39
1246	Effectiveness of early therapeutic intervention in phases one and two after COVID-19 infection: systematic review. 2021 , 67, 302-312	
1245	Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking. 2021 , 22,	12
1244	In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2.	7
1243	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. 2021 ,	19
1242	Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection. 2021 , 41, 1824-1831	12
1241	Bepidil is potent against SARS-CoV-2 in vitro. 2021 , 118,	38
1240	Impact of coronavirus disease 2019 (COVID-19) on US Hospitals and Patients, April-July 2020. 2021 , 1-8	8
1239	Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: Modeling and Screening. 2021 , 61, 1020-1032	11
1238	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. 2021 , 43, 23-32	16
1237	Neurologic Care of COVID-19 in Children. 2020 , 11, 613832	7
1236	SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. 2021 , 17, e1008686	30
1235	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. 2021 , 96, 446-463	23
1234	Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review. 2021 , 13,	9

1233	Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity.	1
1232	The FDA and the COVID-19: A political economy perspective. 2021 , 87, 1210	4
1231	Editorial: COVID-19 immunology and organ transplantation. 2021 , 26, 258-265	
1230	Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. 2021 , 16, 1593-1603	13
1229	Management of immunosuppressants in the era of coronavirus disease-2019. 2021 , 27, 176-183	0
1228	Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning.	2
1227	. 2021 , 13, 12-13	
1226	A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. 2021 , 40, 260-295	6
1225	Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity. 2021 , 9, 2132	1
1224	Scientific effort in combating COVID-19 in obstetrics and gynecology. 2021 , 57, 189-194	0
1223	COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. 2021 , 14, 28	5
1222	A matched cohort study of convalescent plasma therapy for COVID-19. 2021 , 36, 523-532	9
1221	Pharmacokinetics of Orally Administered GS-441524 in Dogs. 2021 ,	5
1220	[COVID-19 in old age-The geriatric perspective]. 2021 , 54, 152-160	5
1219	Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. 2021 , 12, 613422	63
1218	Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. 2021 , 22, 52	17
1217	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. 2021 , 4, e1355	0
1216	Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures. 2021 ,	7

1215	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. 2021 , 12, 631139	43
1214	A 40-Year-Old Man With Tricuspid Atresia, Status Post-Fontan, With Severe COVID-19 Pneumonia and Pneumothorax. 2021 , 3, 187-191	1
1213	Antiviral optical techniques as a possible novel approach to COVID-19 treatment. 2021 , 14, 2130002	3
1212	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. 2021 , 1-36	11
1211	Chemokine Regulation During Epidemic Coronavirus Infection. 2020 , 11, 600369	4
1210	Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19. 2021 , 1-29	2
1209	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. 2021 , 22,	5
1208	Dubious Results of Remdisivir Ultimately in Solidarity; Diversity of Severity of Illness is Doubtful. 2021 , 2, 82-83	
1207	Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. 2021 , 16, e0247665	3
1206	Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells.	1
1205	COVID-19 Associated Stroke: A Single Centre Experience.	
1204	Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?. 2021 , 62, 95-100	5
1203	DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19. 2021 ,	2
1202	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. 2021 , 12, 636989	17
1201	Nanotraps for the containment and clearance of SARS-CoV-2.	1
1200	Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells.	2
1199	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. 2021 , 14, 827-833	3
1198	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. 2021 , 49, 598-622	16

1197	Steroid harms if given early in COVID-19 viraemia. 2021 , 14,	8
1196	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. 2021 , 13,	2
1195	Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection. 2021 , 48, 637-650	3
1194	The impact of COVID-19 on kidney transplantation and the kidney transplant recipient - One year into the pandemic. 2021 , 34, 612-621	13
1193	The detection of SARS-CoV-2 in outpatient clinics and public facilities during the COVID-19 pandemic. 2021 , 93, 2955-2961	8
1192	Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. 2021 ,	39
1191	Diagnostic tool or screening programme? Asymptomatic testing for SARS-CoV-2 needs clear goals and protocols. 2021 , 1, 100002	10
1190	CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. 2021 ,	11
1189	In vitro efficacy of Artemisia extracts against SARS-CoV-2.	2
1188	A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. 2021 , 16, e0245962	21
1187	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. 2021 , 591, 451-457	131
1186	Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection. 2021 ,	3
1185	Ginggolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. 2021 , 11, 45	16
1184	The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. 2021 , 11,	8
1183	Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. 2021 , 372, n311	69
1182	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. 2021 , 193, 43-51	20
1181	Whole-genome sequencing of SARS-CoV-2 in the Republic of Ireland during waves 1 and 2 of the pandemic.	5
1180	Developing statewide remdesivir use criteria. 2021 , 78, 732-735	1

1179	Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir. 2021 , 27, 49-53	
1178	Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. 2021 , 25, 70	5
1177	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. 2021 , 12, 576448	5
1176	The Immunopathology of COVID-19 and the Cannabis Paradigm. 2021 , 12, 631233	9
1175	Modeling the Effect of Population-Wide Vaccination on the Evolution of COVID-19 Epidemic in Canada.	4
1174	HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL.	4
1173	Overall burden and characteristics of COVID-19 in the United States during 2020.	4
1172	Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?. 2021 , 16, 213-218	8
1171	Long-term outcome after intensive care for COVID-19: differences between men and women-a nationwide cohort study. 2021 , 25, 86	9
1170	Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. 2021 , 19, 79	9
1169	High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. 2021 , 12, 627844	14
1168	Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis. 2021 , 36, 470-482	6
1167	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. 2021 , 8, 606755	2
1166	Discovering treatment effectiveness via median treatment effects-Applications to COVID-19 clinical trials. 2021 , 30, 1050-1069	
1165	Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients. 2021 , 12, 613070	10
1164	Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. 2021 ,	9
1163	Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. 2021 , 12, 625678	7
1162	Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. 2021 , 9,	1

1161	Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients. 2021 , 3, 100057	3
1160	Serum β -microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?. 2021 , 16, e0247758	2
1159	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. 2021 , 213, 113157	15
1158	Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. 2021 , 617, 114118	11
1157	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. 2021 , 172, 524-541	38
1156	The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication.	3
1155	Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. 2021 , 15, 513-518	13
1154	Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach. 2021 , 10, 815-825	1
1153	Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. 2021 , 894, 173836	22
1152	COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention. 2021 , 15, 163-171	8
1151	Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system. 2021 , 187, 105015	12
1150	COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium. 2021 , 27, 474.e1-474.e3	1
1149	Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID-19 in West Azerbaijan Province. 2021 , 75, e14108	1
1148	Optimal control of the SIR model in the presence of transmission and treatment uncertainty. 2021 , 333, 108539	10
1147	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. 2021 , 24, 339-355	1
1146	Successful Management of a COVID-19 Positive Infant With Transposition of the Great Arteries. 2021 , 12, 554-556	
1145	Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study. 2021 , 14,	17
1144	Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. 2021 ,	1

1143	Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models. 2021 , 31, e2227	3
1142	Treatment of COVID-19: a review of current and prospective pharmacotherapies. 2021 , 82, 1-9	7
1141	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
1140	ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. 2021 , 16, e0249038	29
1139	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. 2021 , 73, 1849-1856	7
1138	A randomised trial of in critically ill patients with COVID-19: ARMY-1. 2021 , 7,	5
1137	Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. 2021 , 22, 221	8
1136	Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 1015-1027	59.2 251
1135	Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. 2021 , 27, 401-410	44
1134	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. 2021 , 9, 295-304	116
1133	Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. 2021 , 12, 663586	13
1132	The unknown knowns: a graph-based approach for temporal COVID-19 literature mining. 2021 , 45, 687-708	1
1131	Investigation of structural, treatment and clinical characteristics of COVID-19 along with the challenges caused by its prevalence. 2021 ,	
1130	Impact of remdesivir on 28 day mortality in hospitalized patients with COVID-19: February 2021 Meta-analysis.	1
1129	Vaccines and drugs under clinical trials for prevention and treatment of COVID-19. 2021 , 32, 1-7	2
1128	Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. 2021 ,	0
1127	Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. 2021 , 32, 310-315	13
1126	Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C. 2021 , 76, 1947-1948	1

1125	Remdesivir in Patients With Estimated GFR. 2021 , 6, 835-838	9
1124	A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1.	3
1123	Adverse drug reactions in the era of COVID-19. 2021 , 16, 549-550	1
1122	COVID-19 or Influenza, or Both? A Comparison and Algorithmic Approach to Management. 2021 , 13,	0
1121	Development of Equine Immunoglobulin Fragment F(ab) ₂ with High Neutralizing Capability against SARS-CoV-2.	1
1120	Remdesivir. 001857872199980	1
1119	Magnesium Treatment on Methylation Changes of Transmembrane Serine Protease 2 (TMPRSS2). 2021 ,	1
1118	COVID-19 in Children With Liver Disease. 2021 , 9, 616381	10
1117	Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. 2021 ,	4
1116	The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis.	
1115	Development and validation of the RCOS prognostic index: a bedside multivariable logistic regression model to predict hypoxaemia or death in patients with SARS-CoV-2 infection.	1
1114	Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain. 2021 , 12, 603-609	17
1113	Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases. 2021 , 11,	10
1112	Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir. 2021 , 4, 898-907	20
1111	Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses. 2021 ,	5
1110	Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response. 2021 , 15, 021501	2
1109	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. 2021 , 75, e14182	2
1108	Prone Position in Mechanically Ventilated COVID-19 Patients: A Multicenter Study. 2021 , 10,	9

1107	Inhibition of HECT E3 ligases as potential therapy for COVID-19. 2021 , 12, 310	13
1106	Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19. 2021 , 6, 107	5
1105	Discrete Time Multistate Model With Regime Switching for Modeling COVID-19 Disease Progression and Clinical Outcomes. 1-15	3
1104	Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study. 2021 , 178, 106323	8
1103	Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. 2021 , 60, 569-583	29
1102	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. 2021 , 11, 6725	12
1101	Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan.	2
1100	Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study..	11
1099	COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors. 2021 , 61, 1471-1478	4
1098	Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. 2021 , 109, 829-840	21
1097	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. 2021 , 4, e213071	37
1096	Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. 2021 , 76, 1962-1968	27
1095	Remdesivir for COVID-19: Why Not Dose Higher?. 2021 , 65,	5
1094	Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. 2021 , 12, 646676	17
1093	Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19. 2021 , 58, 3347-3361	12
1092	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. 2021 , 31, 325-337	29
1091	COVID-19 and liver disease: mechanistic and clinical perspectives. 2021 , 18, 348-364	90
1090	Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. 2021 , 104, 379-381	17

1089	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. 2021 , 397, 1063-1074	105
1088	Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. 2021 , 1-8	3
1087	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. 2021 , 33, 100773	28
1086	Prophylaxis and treatment of COVID-19 related venous thromboembolism. 2021 , 133, 27-35	10
1085	Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology. 2021 , 8, 649922	7
1084	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. 2021 , 65, 103255	120
1083	Hospital load and increased COVID-19 related mortality in Israel. 2021 , 12, 1904	18
1082	Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes. 2021 ,	20
1081	Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. 2021 , 22, 947-952	1
1080	SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. 2021 , 13, 361-375	3
1079	The Urgent Need for Management of Biological Samples and Data Accessibility in Latin America. 2021 , 12, 620043	1
1078	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. 2021 , 104, 671-676	12
1077	Management of liver disease patients in different clinical situations during COVID-19 pandemic. 2021 , 11, 21	2
1076	Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. 2021 , 7,	3
1075	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. 2021 , 104, 7-14	9
1074	Current evidence for COVID-19 therapies: a systematic literature review. 2021 , 30,	11
1073	Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study. 2021 , 33, 101297	20
1072	Real-life use of remdesivir in hospitalized patients with COVID-19. 2021 , 34, 136-140	6

1071	SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. 2021 , 25, e13986	5
1070	The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5. 2021 , 29, 109	
1069	Biomarkers of Cardiac Stress and Cytokine Release Syndrome in COVID-19: A Review. 2021 , 18, 163-168	3
1068	Renal Manifestations of Covid-19: Physiology and Pathophysiology. 2021 , 10,	9
1067	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. 2021 , 96, 601-618	10
1066	Antivirals with common targets against highly pathogenic viruses. 2021 , 184, 1604-1620	24
1065	Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study. 2021 , 10, e24211	2
1064	A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19.	8
1063	High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics. 2021 , 3, FDD55	6
1062	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. 2021 , 104, 433-440	18
1061	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. 2021 , 17, 1277-1291	1
1060	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.	5
1059	Significant Inhibition of Porcine Epidemic Diarrhea Virus In Vitro by Remdesivir, Its Parent Nucleoside and 5'-N-hydroxycytidine. 2021 , 36, 997-1005	2
1058	Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. 2021 , 34, 473-477	6
1057	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. 2021 , 16, e0247251	14
1056	Twenty articles that critical care clinicians should read about COVID-19. 2021 , 47, 337-341	3
1055	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. 2021 , 29, 1223-1230	13
1054	Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. 2021 , 44, 1801-1814	20

1053	Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. 2021 , 33, 479-498	77
1052	RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. 2021 , 213, 113201	57
1051	Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.	
1050	Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K- β mTOR/BRD4 inhibitor. 2021 ,	8
1049	Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis. 2021 , 21, 247	11
1048	COVID-19: Potential Repurposing Drugs. 2021 ,	2
1047	Uptake of treatment practice standards during a pandemic in an academic medical system. 2021 , 1-2	
1046	A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon α and their combinations.	
1045	Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. 2021 , 31, e2228	4
1044	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). 2021 , 45, 104-121	1
1043	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. 2021 , 10,	3
1042	Amantadine Inhibits SARS-CoV-2 In Vitro. 2021 , 13,	18
1041	Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa.	22
1040	A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare. 2021 , 8, ofab100	2
1039	Telehealth follow up in emergency department patients discharged with COVID-like illness and exertional hypoxia. 2021 , 49, 426-430	4
1038	Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19. 2021 , 12, 510-517	8
1037	The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. 2021 , 11, 5433	12
1036	The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review. 2021 , 12, 645194	22

1035	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. 2021 , 31, e2231	64
1034	Making science computable: Developing code systems for statistics, study design, and risk of bias. 2021 , 115, 103685	2
1033	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. 2021 , 13,	6
1032	COVID-19: Die Rolle der Intensivmedizin. 2021 , 29, 11-14	
1031	Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?. 2021 , 12, 155	5
1030	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. 2021 , 29, 343-366	6
1029	Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. 2021 , 199, 143-148	56
1028	Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department. 2021 , 61, 298-313	5
1027	Global epidemiology of coronavirus disease 2019 and lessons for effective control of this and future pandemics. 2021 , 7, 78-87	
1026	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. 2021 , 22, 1257-1266	4
1025	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: Activity against SARS-CoV-2 and Potential Mechanisms. 2021 , 6, 7454-7468	20
1024	Inhibition of Human Coronaviruses by Antimalarial Peroxides. 2021 , 7, 1985-1995	5
1023	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2021 , 16, e0248132	20
1022	COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment. 2021 , 104, 426-432	12
1021	Reactive arthritis after COVID-19. 2021 , 14,	17
1020	Deciphering the state of immune silence in fatal COVID-19 patients. 2021 , 12, 1428	34
1019	Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. 2021 , 21, 308	33
1018	Diabetes mellitus in combination with COVID-19: modern views on therapy. 2021 , 8-20	

1017	Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain.	
1016	SARS-CoV-2/COVID-19 Aktualisierte Empfehlungen zu Diagnostik und Therapie. 2021 , 29, 80-89	1
1015	Exploration of interethnic variation and repurposed drug efficacy in the treatment of SARS-CoV-2 Infection (COVID-19).	
1014	How to Treat COVID-19 Patients at Home in the Italian Context: An Expert Opinion. 2021 , 13, 251-258	4
1013	Temporal variations in the severity of COVID-19 illness by race and ethnicity. 2021 , 4, 166-173	1
1012	Can Cancer Survivors Donate Convalescent Plasma for the Treatment of COVID-19?. 2021 , 42, 021-024	
1011	Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation. 2021 , 61, 2016-2025	2
1010	Effects of Doxycycline on Replication of Feline Coronavirus. 2021 , 10,	2
1009	COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.	1
1008	Combination therapy protects macaques against advanced Marburg virus disease. 2021 , 12, 1891	10
1007	Exertional hypoxia in patients without resting hypoxia is an early predictor of moderate to severe COVID-19. 2021 , 16, 2097-2103	0
1006	Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2. 2021 , 2, 025024	7
1005	The Economic, Climate Change and Public Health Edges of the Geopolitics of COVID-19: An Exploratory Bibliometric Analysis.	1
1004	A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors.	
1003	Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation. 2021 , 7, e06435	5
1002	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	11
1001	Tenofovir-based PrEP for COVID-19: an untapped opportunity?. 2021 , 35, 1509-1511	4
1000	Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. 2021 , 110, 1002-1017	5

999	Remdesivir: An Antiviral Still Seeking a Raison d'Être. 2021 , 73, 1857-1859	
998	Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19). 2021 , 93, 2631-2634	9
997	Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. 2021 , 12, 635371	21
996	Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic. 2021 , 49, 1427-1438	30
995	The find of COVID-19 vaccine: Challenges and opportunities. 2021 , 14, 389-416	18
994	Management and outcomes of a COVID-19 outbreak in a nursing home with predominantly Black residents. 2021 , 69, 1155-1165	6
993	Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines. 2021 ,	14
992	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. 2021 , 18, e1003415	36
991	AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19. 2021 , 65,	54
990	COVID-19 vaccines: The status and perspectives in delivery points of view. 2021 , 170, 1-25	127
989	COVID-19: Risk Factors Associated with Infectivity and Severity. 2021 , 93, e13039	14
988	Clinical trial preparations for the next pandemic. 2021 , 102, 106292	1
987	A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections. 2021 ,	5
986	Drug repurposing for COVID-19 via knowledge graph completion. 2021 , 115, 103696	28
985	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. 2021 , 53, 435-444	62
984	The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. 2021 , 135, 111200	32
983	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. 2021 , 57,	76
982	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. 2021 , 4, 1096-1110	31

981	Length of remdesivir treatment in patients with severe COVID-19. 2021 , 17, 200276	1
980	Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS-CoV-2.	
979	BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review. 2021 ,	
978	A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.	
977	Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus. 2021 ,	2
976	Experimental therapies under investigation for COVID-19. 2021 , 11, 187-193	2
975	Medical publishing during the COVID-19 pandemic: then and now. 2021 , 51, 1101-1106	2
974	The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations. 2021 , 26, 220-239	4
973	The Effect of Famotidine on Hospitalized Patients with COVID-19: a Systematic Review and Meta-analysis.	
972	COVID-19 and obesity: what is known about the features of pathogenesis and treatment?. 2021 , 2, 17-23	1
971	Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. 2021 , 7, 55	10
970	Remdesivir as a tool to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact.	0
969	Testimonies From the Pandemic Shore. 2021 , 30, 88-90	0
968	Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19. 2021 , 13, e13687	
967	COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. 2021 , 28, 22241-22264	15
966	The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection. 2021 ,	3
965	Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. 2021 , 17, e1008752	21
964	Health Indicators in Hospitalized Patients With SARS-CoV-2 Pneumonia: A Comparison Between the First and Second Wave. 2021 , 57, 717-717	3

963	CD47 as a potential biomarker for the early diagnosis of severe COVID-19.	1
962	CRISPR systems: Novel approaches for detection and combating COVID-19. 2021 , 294, 198282	14
961	Drug discovery and development targeting the life cycle of SARS-CoV-2. 2021 , 1, 151-165	3
960	Extensive environmental contamination and prolonged severe acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant recipients with clinical and virologic benefit with remdesivir. 2021 , 1-3	4
959	Severe covid-19 pneumonia: pathogenesis and clinical management. 2021 , 372, n436	79
958	Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?". 2021 , 65,	2
957	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. 2021 , 246, 1533-1540	1
956	Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?. 2021 , 14, 315-322	2
955	Human coronaviruses and therapeutic drug discovery. 2021 , 10, 28	5
954	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. 2021 , 41,	6
953	Cyclodextrins in Antiviral Therapeutics and Vaccines. 2021 , 13,	10
952	COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. 2021 , 254, 307-331	29
951	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. 2021 , 34, 108837	13
950	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). 2021 , 27, 389-395	19
949	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. 2021 , 1-14	4
948	Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study. 2021 , 8, 632933	8
947	Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV).	2
946	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. 2021 , 17, 24	7

945	Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. 2021 , 9, 622898	75
944	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. 2021 , 12, 632677	28
943	Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial.	6
942	The first 12 months of COVID-19: a timeline of immunological insights. 2021 , 21, 245-256	140
941	Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. <i>New England Journal of Medicine</i> , 2021 , 384, 867-869	59.2 31
940	Bridging Learning in Medicine and Citizenship During the COVID-19 Pandemic: A Telehealth-Based Case Study. 2021 , 7, e24795	2
939	Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients.	1
938	Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp3 Papain-like Protease.	
937	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. 2021 , 13, 259-284	12
936	Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C. 2021 , 149, 110537	4
935	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. 2021 , 76, 1865-1873	3
934	Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits. 2021 , 19, 1245-1258	4
933	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. 2021 , 100, e25532	
932	What the History of Medical Care for Acute Lung Inflammation Teaches Us. 1-5	
931	Perspectives on Drug Repurposing. 2021 , 28, 2085-2099	8
930	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. 2021 , 3, 1-18	3
929	Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. 2021 , 53, 559-580	5
928	The Role of Advance Purchasing Commitments in Government Drug Price Negotiations: Lessons From the COVID-19 Response. 2021 , 111, 652-657	1

927	Etiologies of Delirium in Consecutive COVID-19 Inpatients and the Relationship Between Severity of Delirium and COVID-19 in a Prospective Study With Follow-Up. 2021 , 33, 210-218	4
926	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response. 2021 , 76, 1651-1652	
925	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in Kidney transplant patients: A case series and literature review. 2021 , 35, 17	
924	A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report.	1
923	The COVID-19 Vaccines: Recent Development, Challenges and Prospects. 2021 , 9,	34
922	Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine -Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. 2021 , 64, 5001-5017	25
921	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. 2021 , 9, 436-446	3
920	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. 2021 , 24, 102367	34
919	2020 Year in Review: Pharmacologic Treatments for COVID-19. 2021 , 66, 1167-1172	2
918	Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. 2021 , 35, 108959	77
917	Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. 2021 , 4, e216842	11
916	Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. 2021 , 81, 1548-1552.e4	39
915	Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Systematic Review of the Literature and Challenges. 2021 , 37, 266-282	5
914	Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. 2021 , 13,	24
913	Clinical Trends Among U.S. Adults Hospitalized with COVID-19, March-December 2020.	2
912	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. 2021 , 30, 694-706	13
911	Sex and gender differences in COVID-19: More to be learned!. 2021 , 3, 100011	9
910	Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. 2021 , 9, 2205-2217	0

909 . **2021**, 193, E495-E496

908 The Neurobiology of Modern Viral Scourges: ZIKV and COVID-19. **2021**, 10738584211009149 1

907 Modeling the first wave of Covid-19 pandemic in the Republic of Cyprus. **2021**, 11, 7342 1

906 Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp12/7/8 RNA-dependent RNA Polymerase.

905 Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. **2021**, 86, 34-40 39

904 Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020. **2021**, 4, e216556 34

903 Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. **2021**, 27, 668-676 19

902 Nanocarrier vaccines for SARS-CoV-2. **2021**, 171, 215-239 37

901 Severe acute respiratory syndrome coronavirus 2 infection and critically ill children. **2021**, 33, 286-291 2

900 Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease 2019 Pandemic. **2021**, 190, 2339-2349 2

899 Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state. **2021**, 11, e042549 2

898 Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma. **2021**, 5

897 New drug approvals for 2020: Synthesis and clinical applications. **2021**, 215, 113284 9

896 Compassionate Use of Remdesivir in Children With Severe COVID-19. **2021**, 147, 23

895 Mortality in mechanically ventilated patients with COVID-19: a systematic review. **2021**, 18, 457-471 4

894 Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al. **2021**, 105, 686-687 1

893 Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. **2021**, 13, 3

892 In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. **2021**, 76, 1874-1885 33

891	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. 2021 , 19, 1331-1339	2
890	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. 2021 , 11, 9023	21
889	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. 2021 , 12, 660087	14
888	Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. 2021 , 18,	27
887	Neutralizing Antibody Therapeutics for COVID-19. 2021 , 13,	44
886	Trend towards reduction in COVID-19 in-hospital mortality. 2021 , 3, 100059	0
885	Case fatality rates for COVID-19 are higher than case fatality rates for motor vehicle accidents for individuals over 40 years of age.	
884	A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2. 2021 ,	
883	Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study. 2021 , 25, 148	6
882	The Value of a Regional Living COVID-19 Registry and the Challenges of Keeping It Alive.	
881	Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study.	1
880	Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of COVID-19 patients in Japan.	1
879	Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase.	1
878	High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. 2021 , 12, 877-888	28
877	Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review. 2021 , 44, 635-644	8
876	COVID-19: Antiviral Tedavi.	
875	A clinician's primer on epidemiology for COVID-19. 2021 , 2, 384-394	
874	Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a randomised, double-blinded, phase 2/3, placebo-controlled trial.	

873	Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy. 2021 , 2021, 6648199	12
872	Cardiovascular protective properties of oxytocin against COVID-19. 2021 , 270, 119130	12
871	Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19". 2021 , 57, 65-66	1
870	Quest for a Cure: Potential Small-Molecule Treatments for COVID-19, Part 2. 2021 , 25, 1089-1111	6
869	The race for antiviral drugs to beat COVID - and the next pandemic. 2021 , 592, 340-343	39
868	A 10-Year-Old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir. 2021 ,	2
867	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. 2021 , 10,	9
866	S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie □ AWMF-Register Nr. 021-031 □Stand: 07.01.21. 2021 , 59, 345-359	4
865	Anti-SARS-CoV-2 Activity of Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives. 2021 , 84, 1261-1270	33
864	Decreased COVID-19 Mortality-A Cause for Optimism. 2021 , 181, 478-479	11
863	A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR).	9
862	Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. 2021 , 13,	3
861	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. 2021 , 12, 2295	48
860	Systemic and organ-specific immune-related manifestations of COVID-19. 2021 , 17, 315-332	67
859	Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. 2021 , 16, e0250555	111
858	Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man. 2021 , 193, E612-E615	8
857	Remdesivir for the treatment of COVID-19 in pregnancy. 2021 , 93, 4114-4119	2
856	Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. 2021 , 37, 283-291	3

855	COVID-19 Data Utilization in North Carolina: Qualitative Analysis of Stakeholder Experiences (Preprint).	
854	Ivermectin for preventing and treating COVID-19.	8
853	Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro. 2021 , 61, 2302-2312	28
852	Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors. 2021 ,	1
851	Rapid clinical evolution for COVID-19 translates into early hospital admission and unfavourable outcome: a preliminary report. 2021 , 16, 744	
850	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. 2021 , 394, 839-852	2
849	Evaluating alternative hypotheses to explain the downward trend in the indices of the COVID-19 pandemic death rate. 2021 , 9, e11150	1
848	SARS-CoV-2/COVID-19 Aktualisierte Empfehlungen zu Diagnostik und Therapie. 2021 , 56, 277-287	
847	Emerging therapeutic targets for sepsis. 2021 , 25, 175-189	2
846	Fast and efficient purification of SARS-CoV-2 RNA dependent RNA polymerase complex expressed in Escherichia coli. 2021 , 16, e0250610	0
845	Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129. 2021 , 117, 1823-1840	5
844	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. 2021 , 104, 368504211016936	2
843	Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study. 2021 , 10, 53	5
842	Corona viruses: reaching far beyond the common cold. 2021 , 21, 207-213	0
841	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. 2021 , 11, 1336-1344	8
840	COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes. 2021 , 16, 1629-1639	2
839	Outcomes of non-COVID-19 critically ill patients during the COVID-19 pandemic : A retrospective propensity score-matched analysis. 2021 , 133, 942-950	2
838	A Perspective on COVID-19 Management. 2021 , 10,	3

837	SARS-CoV-2 is detectable using sensitive RNA saliva testing days before viral load reaches detection range of low-sensitivity nasal swab tests. 2021,	11
836	Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. 2021, 897, 173926	33
835	Racial and Ethnic Differences and Clinical Outcomes of COVID-19 Patients Presenting to the Emergency Department. 2021,	7
834	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. 2021, 3, 100041	16
833	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. 2021, 66, 103319	11
832	Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir. 2021,	6
831	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. 2021, 9,	8
830	Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. 2021, 178, 2339-2350	32
829	Possible link between higher transmissibility of B.1.617 and B.1.1.7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity.	7
828	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. 2021, 26, 532-551	11
827	Para-infectious anti-GD2/GD3 IgM myelitis during the Covid-19 pandemic: Case report and literature review. 2021, 49, 102783	10
826	RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. 2021, 103, 106330	3
825	Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial.	10
824	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. <i>New England Journal of Medicine, 2021, 384, 1503-1516</i>	59.2 374
823	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. 2021, 8, ofab153	5
822	Risk Factors and a Scoring System to Predict ARDS in Patients with COVID-19 Pneumonia in Korea: A Multicenter Cohort Study. 2021, 2021, 8821697	1
821	Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. 2021, 9, 576-586	
820	Spike Protein Targeting Nano-Glue that Captures and Promotes SARS-CoV-2 Elimination.	0

8 ₁₉	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. 147775092110114	0
8 ₁₈	Novel Human Lung Tissue Model for the Study of SARS-CoV-2 Entry, Inflammation and New Therapeutics.	1
8 ₁₇	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
8 ₁₆	Management considerations for stroke-like episodes in MELAS with concurrent COVID-19 infection. 2021 , 268, 3988-3991	1
8 ₁₅	Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp14/nsp10 Exoribonuclease.	
8 ₁₄	IL-6 modulation for COVID-19: the right patients at the right time?. 2021 , 9,	12
8 ₁₃	A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. 2021 ,	2
8 ₁₂	Analysis of a COVID-19 Clinical Trial to Emphasize Experimental Design and Quantitative Reasoning in an Introductory Biology Course. 2021 , 22,	0
8 ₁₁	Current COVID-19 treatments: Rapid review of the literature. 2021 , 11, 10003	13
8 ₁₀	Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use. 2021 , 147,	
8 ₀₉	High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?. 2021 , 16, 1329-1330	4
8 ₀₈	Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?. 2021 ,	7
8 ₀₇	Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field. 2021 , 9,	1
8 ₀₆	Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan. 2021 , 3, 62-66	5
8 ₀₅	Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection: A retrospective observational study. 2021 , 25, 390-400	3
8 ₀₄	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. 2021 , 218,	79
8 ₀₃	Stratifying Deterioration Risk by Acuity at Admission Offers Triage Insights for Coronavirus Disease 2019 Patients. 2021 , 3, e0400	2
8 ₀₂	A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. 2021 , 13,	6

801	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. 2021 , 20, 88	12
800	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. 2021 , 14, e007957	10
799	Network medicine framework for identifying drug-repurposing opportunities for COVID-19. 2021 , 118,	77
798	Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. 2021 , 9,	27
797	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9
796	2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. 2021 , 147, 154-160	18
795	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. 2021 , 12, 2016	31
794	Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. 2200060	0
793	Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story. 1-4	3
792	Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study. 2022 , 11, 941	0
791	COVID-19 pandemic surges can induce bias in trials using response adaptive randomization: A simulation study.	
790	Pharmacy students' knowledge and confidence of COVID-19 following an interactive didactic class.	
789	Remdesivir powders manufactured by jet milling for potential pulmonary treatment of COVID-19. 1-11	1
788	A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19. 2022 , 2022, 1-8	1
787	Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. 2022 , 35, 271-279	2
786	Sotrovimab lowers the risk of COVID -19 related hospitalization or death in a large population cohort in the United Arab Emirates.	0
785	Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. 2022 , 15, 831	0
784	New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.	2

- 783 Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2. **2022**, 18, e1010330 0
- 782 Human lung organoids as a model for respiratory virus replication and countermeasure performance in human hosts. **2022**, 0
- 781 Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study. 0
- 780 Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies. 3
- 779 65-Year-Old Man With Weight Loss and Dyspnea on Exertion. **2022**, 97, 1363-1368
- 778 A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) for the treatment of severe COVID-19 pneumonia: First experience from Africa. **2022**, 17, e0270594 0
- 777 4?-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness. 0
- 776 COVID-19 Vaccine and Long COVID: A Scoping Review. **2022**, 12, 1066 1
- 775 A Path-Based Analysis of Infected Cell Line and COVID-19 Patient Transcriptome Reveals Novel Potential Targets and Drugs Against SARS-CoV-2. 13, 0
- 774 Epidemiological impact of COVID-19 in India: Country with second foremost positive cases in the world. **2022**, 100007
- 773 Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma. **2022**, 25, 27-35 0
- 772 Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. **2022**, 153, 113368 1
- 771 Synthesis and structure-activity relationship study of saponin-based membrane fusion inhibitors against SARS-CoV-2. **2022**, 127, 105985 0
- 770 Coronaviruses. **2023**, 277-306
- 769 Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. **2022**, 19, 8845 1
- 768 Outcomes of COVID-19 in a Large Cohort of Lung Transplant Recipients: A Retrospective Study. **2022**, 3, 257-266
- 767 Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. 3
- 766 Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. **2022**, 0

- 765 Antiviral activity of medicinal plant-derived products against SARS-CoV-2. 153537022211089 2
- 764 Don't Look Up! Your Science Herd Immunity or Herd Mentality?. **2022**, 10, 1463
- 763 Gastrointestinal prophylaxis for COVID-19: An illustration of severe bias arising from inappropriate comparators in observational studies. **2022**,
- 762 The collaborative research and service delivery partnership between the United States healthcare system and the U.S. Military Health System during the COVID-19 pandemic. **2022**, 20,
- 761 Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies. 13, 0
- 760 Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. **2022**, 58, 1007 0
- 759 Cannabidiol As a Treatment for COVID-19 Symptoms? A Critical Review.
- 758 Safety and biodistribution of Nanoligomers targeting SARS-CoV-2 genome for treatment of COVID-19.
- 757 Systemic sclerosis in the time of COVID-19. **2022**, 4, e566-e575 1
- 756 The COVID-19 Pandemic and HIV. **2021**, 425-428
- 755 Alternative role of motif B in template dependent polymerase inhibition. **2022**, 35, 407-412 0
- 754 The Future of Parenting Programs: I Design. **2022**, 22, 201-234 0
- 753 A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 Omicron in vivo.
- 752 SARS-CoV-2 Is Not Special, but the Pandemic Is: The Ecology, Evolution, Policy, and Future of the Deadliest Pandemic in Living Memory. **2022**, 51,
- 751 Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study. **2022**, 17, e0271501 1
- 750 Case report: Successful outcome of COVID-19 in the context of autologous hematopoietic stem cell transplantation: The impact of the anti-SARS-CoV-2 vaccine and early remdesivir. 9,
- 749 Patients with myeloproliferative neoplasms and COVID -19 have increased rates of arterial thrombosis. **2022**, 6, 0
- 748 Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UK.

747	Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention. 2022 , 17, e0271303	0
746	Reinfection with SARS-CoV-2 in a patient undergoing chemotherapy for lymphoma: Case report.	0
745	Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin. 2022 , 17, e0272377	0
744	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. 2022 , 11, 4464	1
743	Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis. 2022 , 14, 3746	1
742	Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial. 2022 , 9,	0
741	The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides. 2022 , 15, 909	3
740	Thymosin α 1 for COVID-19: Look before You Leap!. 2022 , 26, 892-893	
739	Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review. 2022 , 11, 1609	6
738	Role of aging in BloodBrain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19. 2022 , 19,	1
737	Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.	3
736	COVID-19 and Implications on the Liver. 2022 ,	2
735	Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia. 2022 ,	
734	Computational and Experimental Approaches Identify Beta-Blockers as Potential SARS-CoV-2 Spike Inhibitors. 2022 , 7, 27950-27958	0
733	Activation of the urotensin-II receptor by anti-COVID-19 drug remdesivir induces cardiomyocyte dysfunction.	
732	Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2.	2
731	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.	1
730	Absolute binding free energies of mucroporin and its analog mucroporin-M1 with the heptad repeat 1 domain and RNA-dependent RNA polymerase of SARS-CoV-2. 1-12	

- 729 Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study. 0
- 728 Corporate Moral Responsibility, Distributive Justice, the Common Good, and Catholic Social Teaching: The Case of Gilead Sciences and Remdesivir. 002436392211162
- 727 PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells.
- 726 Environmental and ecotoxicological effects of drugs used for the treatment of COVID 19. 10, 0
- 725 The mechanism of RNA capping by SARS-CoV-2. 0
- 724 A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalescence. **2022**, 12, 0
- 723 Azithromycin through the Lens of the COVID-19 Treatment. **2022**, 11, 1063 1
- 722 Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2. 13,
- 721 The Pharmacist's Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications. **2022**, 10, 94
- 720 Characterization of Pathogen Inactivated COVID -19 Convalescent Plasma and Responses in Transfused Patients. 0
- 719 Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review. Publish Ahead of Print, 0
- 718 The Remarkable Roles of the Receptor for Advanced Glycation End Products (RAGE) and Its Soluble Isoforms in COVID-19: The Importance of RAGE Pathway in the Lung Injuries.
- 717 Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. **2022**, 23, 9297 1
- 716 RK-33, a small molecule inhibitor of host RNA helicase DDX3, suppresses multiple variants of SARS-CoV-2. 13, 1
- 715 Infection, Rejection, and the Connection. Publish Ahead of Print, 1
- 714 Joint inference for competing risks data using multiple endpoints.
- 713 Treatments for the Infection by SARS-CoV-2.
- 712 Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City. 0

711	Care of the Seriously Ill Patient with SARS CoV-2. 2022,	
710	Within-host dynamics of SARS-CoV-2 infection: A systematic review and meta-analysis.	0
709	Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States.	
708	Development of a novel score model to predict hyperinflammation in COVID-19 as a forecast of optimal steroid administration timing. 9,	0
707	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. 2022, 28, 2211-2233	
706	The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (Mpro). 2022, 9,	1
705	An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. 2022, 14, 3931	0
704	Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England.	0
703	Influenza. 2022, 400, 693-706	6
702	Peptidic defective interfering gene nanoparticles against Omicron, Delta SARS-CoV-2 variants and influenza A virus in vivo. 2022, 7,	0
701	Mortality analysis in cases of COVID-19 during the second wave at a tertiary care center in western India. 2022, 9, 180-186	
700	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. 10,	
699	Modeling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent RNA Polymerase by DFT/MM-MD: An Unusual Active Site Leading to High Replication Rates.	2
698	Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19).	1
697	Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review. 2022, 11, 2489	0
696	Interfering with nucleotide excision by the coronavirus 3' to 5' exonuclease.	
695	Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania.	0
694	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. 2022, 5,	0

693	Two Years into the COVID-19 Pandemic: Lessons Learned.	4
692	COVID-19 and hospital management costs: the Italian experience. 2022 , 22,	0
691	A review of clinical efficacy data supporting emergency use authorization for COVID -19 therapeutics and lessons for future pandemics.	1
690	Synthesis and Biological Evaluation of Umifenovir Analogues as Anti-SARS-CoV-2 Agents. 2022 , 7,	
689	Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19.	2
688	Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19. Volume 15, 4907-4920	1
687	Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection. 2022 ,	1
686	LENZILUMAB OUTCOMES ACCORDING TO RACE OF COVID-19 PARTICIPANTS IN THE LIVE-AIR PHASE 3 TRIAL.	
685	Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. ard-2022-222954	0
684	NirmatrelvirRemdesivir association for non-hospitalized adults with COVID-19, point of view.	0
683	Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. 13,	0
682	Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study. 2022 , 13,	1
681	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). 2022 ,	
680	Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. 2022 ,	2
679	International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship.	
678	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. 13,	1
677	A Versatile Class of 1,4,4-Trisubstituted Piperidines Block Coronavirus Replication In Vitro. 2022 , 15, 1021	
676	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.	1

675	Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study. 9,	0
674	Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19.	1
673	Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. 2022 , 100735	0
672	Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial.	0
671	Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone.	
670	Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus.	
669	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination.	3
668	Protein Kinase C Inhibitors Reduce SARS-CoV-2 Replication in Cultured Cells.	0
667	Nanotechnology-based strategies against SARS-CoV-2 variants.	5
666	A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.. 2022 , 153, 113499	0
665	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. 2022 , 111, 109161	2
664	Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. 2022 , 319, 198882	0
663	Gastric Aspiration and Ventilator-Induced Model of Acute Respiratory Distress Syndrome in Swine. 2022 , 280, 280-287	
662	Consequences of COVID-19 on the cardiovascular and renal systems. 2022 , 100, 31-38	0
661	Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. 13,	1
660	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. 2022 , 29,	2
659	Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy. 2022 , 9, e001332	0
658	A Pilot Trial of Thymalfasin (Thymosin- α 1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.	0

- 657 Synthesis of Novel N4-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents. **2022**, 15, 1144 ○
- 656 MultiOMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells. ○
- 655 Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. **2022**, 184, 106424 ○
- 654 Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study. **2022**, 15, 1061-1064 ○
- 653 The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF- κ B signaling. **2022**, 25, 105066 ○
- 652 Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study. **2022**, 4, e727-e737 2
- 651 The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection. **2022**, 154, 113625 ○
- 650 COVID-19: Vaccines and therapeutics. **2022**, 75, 128987 ○
- 649 COVID-19 in patients with B cell immune deficiency. **2022**, 510, 113351 ○
- 648 Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. **2022**, 4, 100054 ○
- 647 Remdesivir Use and Controversies in COVID-19 Pneumonia: Myths and Reality!. **2022**, 4, 15 ○
- 646 Biotechnological Strategies in the Intervention and Treatment of COVID-19. **2022**, 421-442 ○
- 645 Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity. **2022**, 20, 5181-5192 ○
- 644 Identification of Potential Ligands of the Main Protease of Coronavirus SARS-CoV-2 (2019-nCoV) Using Multimodal Generative Neural-Networks. **2022**, 10, 30-47 ○
- 643 Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. **2022**, 16, 117954842211193 ○
- 642 The impact of an antimicrobial stewardship program restriction on remdesivir prescribing. **2022**, 2, ○
- 641 Immunology. **2022**, 181-223 ○
- 640 Pre-hospital Management of COVID-19: Looking for a Future Perspective. **2022**, 395-419 ○

- 639 Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up. **2022**, 14, 1759720X2211164 ○
- 638 Cytokine storm secondary to coronavirus disease-19 pneumonia in a preterm pregnancy: A management and bioethical dilemma. **2022**, 46, 80 ○
- 637 Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2. **2022**, 281-293 ○
- 636 Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological Malignancies. ○
- 635 Green chemistry approaches to drugs that treat epidemic and pandemic diseases. **2022**, 307-331 ○
- 634 COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part I. COVID-19 and Influenza. **2022**, 37, 1-9 ○
- 633 COVID-19 Associated Acute Kidney Injury. **2022**, 21, 94-99 ○
- 632 Searching for potential inhibitors of SARS-COV-2 main protease using supervised learning and perturbation calculations. **2023**, 564, 111709 ○
- 631 Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. **2022**, 10, E807-E817 ○
- 630 Remdesivir-Induced Pancreatitis in a Patient With Coronavirus Disease 2019. **2022**, 51, e88-e89 ○
- 629 Seronegative immunity to SARS-CoV-2: a case study. **2022**, 18, ○
- 628 Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment. 12, ○
- 627 Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study. **2022**, 11, 5066 ○
- 626 The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. 9, ○
- 625 Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report. 2, ○
- 624 Determination of Molnupiravir by Extractive Colorimetric Method from Pharmaceutical Dosage Form. **2022**, 256-258 1
- 623 Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis. **2022**, ○
- 622 Lung Transplantation in Patients With COVID-19-The Early National Experience. **2022**, ○

621	COVID-19 treatments.	0
620	Changing Critical Care Patterns and Associated Outcomes in Mechanically Ventilated Severe COVID-19 Patients in Different Time Periods: An Explanatory Study from Central India. 2022 , 26, 1022-1030	0
619	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. 2022 , 92, 430-436	0
618	COVID-19: Opportunities to Improve Prognosis. 2022 , 92, 404-411	0
617	COVID-19 and Cardiovascular Manifestations. 2022 , 102-136	0
616	The Fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City. 2022 , 37, 339-346	1
615	Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. 2022 , 7, 31935-31944	1
614	Effect of Remdesivir Administration on Occurrence of Major Adverse Cardiac Events in Critically Ill COVID-19 Pneumonia: A Retrospective Observational Study. 2022 , 26, 993-999	0
613	The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.	0
612	A computational approach to drug repurposing using graph neural networks. 2022 , 105992	1
611	Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center. 2022 ,	1
610	Is It Time to Revisit Remdesivir Use for Severe COVID-19?. 2022 , 26, 983-984	1
609	COVID-19 and Kidney Transplantation. 2022 , 21, 238-245	0
608	COVID-19 in the Geriatric Population. 2022 , 343-357	0
607	Succint review on biological and clinical aspects of Coronavirus disease 2019 (COVID-19). 2022 , 125, 356-365	0
606	Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. 2022 , 65, 12044-12054	0
605	A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. 2022 , 100774	2
604	Fluvoxamine for the treatment of COVID-19. 2022 , 2022,	0

603	Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants. 2022 , 17, e0272916	1
602	Fluorine Atoms on C6H5-Corrole Affect the Interaction with Mpro and PLpro Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches. 2022 , 23, 10936	0
601	Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. 13,	0
600	Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS). 2022 ,	0
599	Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study. 1-15	3
598	Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?. 2022 ,	0
597	SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature. Publish Ahead of Print,	0
596	Safety and effectiveness of RBD-specific polyclonal equine F(ab') ₂ fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. 2022 , 17, e0274796	0
595	Race, ethnicity, and health disparities in US children with COVID-19: a review of the evidence and recommendations for the future	1
594	Management of COVID-19: A comprehensive and practical approach. 2022 ,	0
593	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. 2022 , 12, 1456	0
592	Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19. 00216-2022	0
591	Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β Coronaviruses.	0
590	Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized Patients with COVID-19: impact on the length of hospital stay and mortality.	0
589	High throughput Bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 Methyltransferases.	0
588	Political Prescriptions: Three Pandemic Stories. 016224392211238	0
587	Benefits of probiotic use on COVID-19: A systematic review and meta-analysis. 1-13	1
586	A case of COVID -19-associated fulminant myocarditis successfully treated with mechanical circulatory support. 2022 , 10,	0

585	Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression. 2022 , 14, 2045	1
584	Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. 2022 , 14, 4720	4
583	Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). 2022 ,	0
582	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. 2022 ,	0
581	In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs.	0
580	A practical update on the management of patients with COVID-19. 2022 , 22, 468-474	0
579	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era.	0
578	Deep RNA sequencing of intensive care unit patients with COVID-19. 2022 , 12,	0
577	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.	0
576	Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19.	0
575	Lung Organoids as Model to Study SARS-CoV-2 Infection. 2022 , 11, 2758	1
574	Long-Term Health Consequence of Discharged Patients with COVID-19: A Survey of Patients from Hospital Dedicated COVID-19 in 2021. 2022 , 12, 239-246	0
573	A Data Science Approach to Evaluate Drug Effectiveness: Case Study of Remdesivir for Covid-19 Patients in India. 2023 , 691-712	0
572	Thromboembolic Disease and Cardiac Thrombotic Complication in COVID-19: A Systematic Review. 2022 , 12, 889	1
571	A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.	3
570	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. 2022 , 7, 163-169	0
569	A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. 2022 , 12,	1
568	Systematic Review for Remdesivir Use in Pediatric Patients under 3.5 kg with COVID-19. 2022 , 14, 101-108	0

567	SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?. 2022 , 114, 110466	2
566	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. 00236-2022	0
565	Antiviral activity of Cenostigma pluviosum var. peltophoroides extract and fractions against SARS-CoV-2. 1-12	1
564	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. 2022 , 12, 1472	0
563	Coagulopathy during COVID-19 infection: a brief review.	2
562	Informing healthcare operations with integrated pathology, clinical, and epidemiology data: Lessons from a single institution in Kenya during COVID-19 waves. 9,	0
561	Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. 1-14	2
560	Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study.	0
559	Current clinical status of new COVID-19 vaccines and immunotherapy.	0
558	Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab. 12,	1
557	Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.	1
556	RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models. 2022 , 8,	0
555	Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19. 13,	0
554	Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. 13,	0
553	Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 and Covid-19.	3
552	Efficacy of Dexamethasone and Methylprednisolone in Hospitalization Outcomes of COVID-19 Patients: A Comparative Retrospective Study. 2022 , 17,	0
551	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. 1-21	1
550	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.	0

549	Evaluation of S/F94 as a proxy for COVID-19 severity.	0
548	In silico approach identified benzoylguanidines as SARS-CoV-2 main protease (Mpro) potential inhibitors. 1-14	1
547	Bounded-width confidence interval following optimal sequential analysis of adverse events with binary data. 096228022211223	0
546	Exacerbation of Pre-existing Neurological Symptoms With COVID-19 in Patients With Chronic Neurological Diseases: An Updated Systematic Review. 2022,	0
545	A strategy for evaluating antiviral resistance: Application to small molecule drugs/inhibitors against SARS-CoV-2.	0
544	Mortality predictors in patients with COVID-19 pneumonia: a machine learning approach using eXtreme Gradient Boosting model. 2022, 17, 1929-1939	0
543	Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid BilayersAn MD Study. 2022, 12, 941	0
542	Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz.	0
541	Recent advances in small-molecular therapeutics for COVID-19.	0
540	Pharmacokinetic Considerations to Optimize Clinical Outcomes for COVID-19 Drugs. 2022,	0
539	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
538	Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes. 2022, 8,	1
537	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. 2022, 217, 368-378	1
536	Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.	2
535	Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase. Implications for Repurposing Antiviral Agents Against SARS-CoV-2.	0
534	Expanding Perspectives on Integrative Medicine: Promoting Global Health in the COVID-19 Era. 2022, 1, 1-2	0
533	Druggable targets and therapeutic development for COVID-19. 10,	0
532	The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis. 2022,	0

- 531 COVID treatment and in-hospital length of stay inequalities between race in the US over time. 0
- 530 An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges. **2022**, 115279 2
- 529 Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101). 13, 1
- 528 Managing Covid-19 in patients with heart failure: current status and future prospects. 0
- 527 An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. 1-6 0
- 526 Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program. 0
- 525 Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study. 1
- 524 Ganoderma microsporium immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. **2022**, 155, 113766 2
- 523 Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. **2022**, 244, 114803 1
- 522 Machine Learning Techniques for Development of Drugs Against Coronavirus Disease 2019 (COVID-19): A Case Study Protocol. **2021**, 307-325 0
- 521 Safety of remdesivir in 20 children with COVID-19 -case series-. **2022**, 0
- 520 Japanese rapid/living recommendations on drug management for COVID -19: updated guidelines (July 2022). **2022**, 9, 0
- 519 Catholic Social Teaching, Corporate Moral Responsibility, Disaster Capitalism, and Remdesivir Drug. **2022**, 91-108 0
- 518 Analysis of worldwide real-time recovery and death ratio of COVID-19 pandemic. **2022**, 0
- 517 Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. **2022**, 16, 175346662211327 0
- 516 Therapeutic Uses of TheraCourlPolymeric Nanomicelles Against Cancer, Infectious Diseases, and More. **2022**, 473-506 0
- 515 RemCheck: A Novel Drug Validator Application to detect fake Remdesivir, an Anti-Viral Drug for COVID-19. **2022**, 0
- 514 Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19. **2022**, 35, 106-110 0

513	Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia. 2022 , 10, 1949	1
512	Molecular Docking of Active Compounds from Traditional Medicinal Plants as ACE-2 protein (1R4L) inhibitor in searching for COVID-19 drug. 2022 , 4235-4240	0
511	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. 2022 , 101151	3
510	Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea. 2022 , 13, 370-376	0
509	Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?. 2022 ,	2
508	Herbo-mineral formulation, Divya-Swasari-Vati averts SARS-CoV-2 pseudovirus entry into human alveolar epithelial cells by interfering with spike protein-ACE 2 interaction and IL-6/TNF- α /NF- κ B signaling. 13,	0
507	Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19. 2022 , 5, e2238507	0
506	1 β -Cyano Intermediate Enables Rapid and Stereoretentive Access to 1 β -Modified Remdesivir Nucleosides.	0
505	Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection. 2022 , 105427	0
504	Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2. 2022 , 27, 7317	1
503	Covid-19 in kidney transplant recipients. 2022 , 68, 444-448	0
502	Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host.	1
501	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. 2022 , 12, 1605	2
500	Synthesis of Nucleoside and Nucleotide Analogues by Cyclization of the Guanine Base with 1,1,3,3-Tetramethoxypropane. 2022 , 24, 7834-7838	0
499	Considerations for management of patients with diabetes mellitus and acute COVID-19. 13, 802-808	0
498	Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review.	0
497	Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants.	0
496	Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. Volume 16, 3645-3654	1

495	Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report. 2022,	0
494	The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. 2022, 5,	1
493	COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2.	0
492	Torsades de Pointes associated with remdesivir treatment for COVID-19 pneumonia.	0
491	COVID-19 and HSCT (Hematopoietic stem cell transplant). 2022, 101399	0
490	Wave of Invasive Fungal Disease on the Shores of COVID-19: A Case Series of COVID-19 Associated Rhino-Orbital Fungal Rhinosinusitis and Literature Review.	0
489	Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors.	0
488	Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors.	1
487	COVID-19 treatment: A potential cause of acute pancreatitis. 2022, 10,	1
486	Severe COVID-19 Pneumonia in an Unvaccinated Female Treated With Remdesivir. 2022,	0
485	Effect of Remdesivir on moderate to severe COVID-19 patients's outcomes..	0
484	Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia. 2022, 2022, 1-4	0
483	Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies. 2022, 12, 289-306	1
482	Capture and passive predation in times of COVID-19 pandemic.	0
481	A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection.	1
480	Diabetes IN hospital [Glucose and Outcomes in the COVID -19 pandemic (DINGO COVID -19): the 2020 Melbourne hospital experience prior to novel variants and vaccinations.	0
479	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment.	0
478	The efficacy and safety of remdesivir and its combination with other drug for the treatment of COVID-19: a systematic review and meta-analysis.	0

477	Efficacy and safety of three passive immunotherapies for Corona Virus Disease 2019:a system review and network meta-analysis.	0
476	Stay-at-home and face mask policy intentions inconsistent with incidence and fatality during the US COVID-19 pandemic. 10,	0
475	Psychotropic drug repurposing for COVID-19: a Systematic Review and Meta-Analysis. 2022 ,	0
474	Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.	0
473	Indirect Virus Transmission via Fomites Can Counteract Lock-Down Effectiveness. 2022 , 19, 14011	0
472	Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.	1
471	CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. 2022 , 18, e1010479	0
470	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13,	1
469	Therapeutic advances in COVID-19.	4
468	Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. 2022 , 12,	0
467	Respiratory function and CT abnormalities among survivors of COVID-19 pneumonia: a nationwide follow-up study. 2022 , 9, e001347	0
466	Monoclonal antibodies for the treatment of COVID-19 infection in children. 1-7	0
465	Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients.	1
464	Efficient Targeted Delivery of Bifunctional Circular Aptamer ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation.	0
463	COVID-19 Therapeutics and Considerations for Pregnancy. 2022 ,	0
462	Vaccination efficacy in patients with chronic lymphocytic leukemia. 1-15	0
461	Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants.	1
460	Risk factors for severe infection and mortality In patients with COVID -19 in patients with multiple myeloma and AL amyloidosis.	1

- 459 Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. 2202556 ○
- 458 Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients. ○
- 457 COVID-19: dealing with ventilator shortage. **2022**, 28, 652-659 ○
- 456 Clinical and mycological investigations of post-COVID -19 acute invasive fungal sinusitis. ○
- 455 Translocation pause of remdesivir-containing primer/template RNA duplex within SARS-CoV-2 RNA polymerase complexes. 9, ○
- 454 Evaluation of Drug-Induced Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection. **2022**, 10, 2045 1
- 453 How pragmatic are randomized trials of Remdesivir and Favipiravir for in-hospital treatment of Covid-19: A descriptive methodological review of trial design using the PRECIS-2 framework. **2022**, ○
- 452 Identification of Potential Antiviral Disaccharide Leading Compounds against SARS-CoV-2 through A Computer Aided Study. ○
- 451 An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. **2022**, 14, 2429 ○
- 450 Racial and ethnic variation in COVID-19 care, treatment, and outcomes: A retrospective cohort study from the MiCOVID-19 registry. **2022**, 17, e0276806 ○
- 449 Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. **2022**, 12, ○
- 448 B-cell malignancies and COVID-19: a narrative review. **2022**, ○
- 447 Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir. ○
- 446 Post-COVID-19 respiratory problems: burden and management. Publish Ahead of Print, ○
- 445 COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12 ○
- 444 Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: A retrospective multicenter study. **2022**, 16, 100207 ○
- 443 A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. **2022**, 12, 1758 2
- 442 Discovery and structural characterization of chicoric acid as a SARS-CoV-2 nucleocapsid protein ligand and RNA binding disruptor. **2022**, 12, ○

441	Post-exposure-vaccine-prophylaxis against COVID-19.	1
440	Remdesivir in solid organ recipients for COVID-19 pneumonia. 2022,	0
439	Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities. 2022, 77, 102170	1
438	Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. 2022, 77, 102172	0
437	Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. 2022, 244, 114857	1
436	Use of cerebral organoids to model environmental and gene x environment interactions in the developing fetus and neurodegenerative disorders. 2023, 173-200	0
435	Mechanical Circulatory Support in the Era of COVID-19. 2022, 273-281	0
434	Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study. 2023, 55, 101724	0
433	Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection. 2022, 36, 2171-2179	1
432	Antiviral use in liver function abnormalities and Covid-19 patients: Serial cases. 2022, 104876	0
431	In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs.	1
430	Immunocompromised Patients with Protracted COVID-19: a Review of [Long Persisters]	1
429	Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort. 2022, 12,	0
428	S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie [AWMF-Registernummer: 021-031 [Stand 15. Juni 2022. 2022, 60, 1678-1698	0
427	Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms. 2022, 12,	0
426	Tuberculosis and COVID-19 co-infection in Serbia: Pandemic challenge in a low-burden country. 9,	0
425	Djvu all over again? Monkeypox and the urgent need for randomised controlled trials. 2022,	0
424	COVID-19 in Russia: Evolution of Views on the Pandemic. Report II. 2022, 77, 291-306	1

423	Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan. 2022,	0
422	Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. 2022, 71,	1
421	Reply to Yan.	0
420	Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). 2022, 11, 6545	0
419	Developmental toxicity of remdesivir, an anti-COVID -19 drug, is implicated by in vitro assays using morphogenetic embryoid bodies of mouse and human pluripotent stem cells.	0
418	Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial. 2022, 28,	1
417	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. 2022,	0
416	Changing trends of patient characteristics and treatment pathways during the COVID-19 pandemic: A cross-sectional analysis of 72,459 inpatient cases from the German Helios database. 10,	0
415	Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model. 2022, 175392	0
414	Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study. 2022, 10, 2299	0
413	Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses. 2022, 12,	1
412	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. 2022,	0
411	Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). 2022, 27,	1
410	A country-based review in COVID-19 related research developments.	0
409	Lung Transplantation for COVID-19 patients and COVID-19 in Lung Transplant Recipients. 2022,	0
408	Test 5- versus 10-day remdesivir treatment in immunocompromised patients with COVID-19.	0
407	THE INFLUENCE OF IMMUNOTROPIC DRUGS ON THE CYTOKINE STORM IN CORONAVIRUS INFECTION (ON THE EXAMPLE OF A CLINICAL CASE). 2022, 11, 77-84	0
406	Prevention is Key to Reducing the Spread of COVID-19 in Long-Term Care Facilities. Volume 15, 6689-6693	0

405	A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future. 1-13	0
404	The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections.	0
403	Diastereo- and enantioselective synthesis of compounds with a trifluoromethyl- and fluoro-substituted carbon centre.	2
402	Bayes Factors for Two-group Comparisons in Cox Regression.	0
401	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.	8
400	Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.	0
399	Distribution of age, sex, race, and ethnicity in COVID-19 clinical drug trials in the United States: A review. 2022 , 123, 106997	0
398	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. 2022 , 443, 120487	2
397	Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario. 2022 , 29,	0
396	Immunomodulators in Mechanically Ventilated Patients With COVID-19: Lessons Learned From Underpowered Trials*. 2022 , 50, 1821-1828	1
395	Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy. 2022 , 57, 101279	1
394	Antiviral Agents. 2023 , 1583-1598.e6	0
393	Human Coronaviruses. 2023 , 1167-1175.e6	0
392	Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. 2023 , 209, 105475	0
391	Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. 2022 , 20,	1
390	COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?. 2022 , 37,	2
389	How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea. 2022 , 37,	0
388	Arzneimittelnutzung unter Pandemiebedingungen. 2022 , 171-187	0

- 387 Role of nanotechnology in diagnosis and disease control with a focus on COVID-19 and future perspectives. **2023**, 269-283 0
- 386 Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1. **2023**, 209, 105481 1
- 385 Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. **2023**, 157, 114037 0
- 384 An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus. **2023**, 152, 106433 0
- 383 COVID-19 signalome: Potential therapeutic interventions. **2023**, 103, 110559 0
- 382 The Evolving Impact of Myocardial Injury in Patients With COVID-19 Amid the Omicron Wave of the Pandemic. **2023**, 190, 54-60 1
- 381 Is remdesivir-induced symptomatic bradycardia persistent? A two case report of COVID-19 infection. **2022**, 0 0
- 380 Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus. **2022**, 10, 251513552211448 0
- 379 Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study. 54, 0
- 378 Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. **2022**, 27, 92 0
- 377 Reduction in the rate of mortality of moderate to severe COVID 19 infected patients with the use of remdesivir - A Tertiary Care Hospital-based retrospective observational study. **2022**, 16, 296 2
- 376 Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea. **2022**, 37, 0
- 375 Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. Publish Ahead of Print, 0
- 374 Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*. **2023**, 51, 103-116 1
- 373 High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases. **2022**, 17, e0274343 0
- 372 A study protocol of external validation of eight COVID-19 prognostic models for predicting mortality risk in older populations in a hospital, primary care, and nursing home setting. 0
- 371 Impact of Zinc, Vitamins C and D on Disease Prognosis among Patients with COVID-19 in Bangladesh: A Cross-Sectional Study. **2022**, 14, 5029 1
- 370 IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. 12, 0

- 369 Honey and Nigella sativa against COVID -19 in Pakistan (HNS-COVID-PK): A multicenter placebo-controlled randomized clinical trial. ○
- 368 The Role of VV-ECMO in Severe COVID-19 ARDS. ○
- 367 Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells. **2022**, 14, 2620 ○
- 366 Predicting Oxygen Utilization & Nurse Staffing Needs For COVID-19. **2022**, ○
- 365 An Overview of Repurposed Drugs for Potential COVID-19 Treatment. **2022**, 11, 1678 ○
- 364 Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS-CoV-2 Delta variant: A comprehensive review. ○
- 363 Identification of Transcriptome Biomarkers for Severe COVID-19 with Machine Learning Methods. **2022**, 12, 1735 ○
- 362 Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. **2022**, 23, 14462 ○
- 361 Discovering new potential inhibitors to SARS-CoV-2 RNA dependent RNA polymerase (RdRp) using high throughput virtual screening and molecular dynamics simulations. **2022**, 12, 1 ○
- 360 Incidence and Microbiology of Hospital-Acquired Infections in COVID-19 Patients between the First and the Second Outbreak of the SARS-CoV-2 Pandemic: A Retrospective, Observational Study. **2022**, 10, 2372 ○
- 359 A Validated Potentiometric Titration Method for Quantitative Determination of Molnupiravir from Pharmaceutical Preparation. **2022**, 439-442 ○
- 358 Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection. 11, 435-442 ○
- 357 Antiviral Treatment of COVID-19 Pneumonia. **2022**, ○
- 356 Molecular Function of cGAS-STING in SARS-CoV-2: A Novel Approach to COVID-19 Treatment. **2022**, 2022, 1-10 ○
- 355 Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent. **2022**, 65, 15789-15804 1
- 354 Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. 13, ○
- 353 Insights into the Dynamics and Binding of Two Polyprotein Substrate Cleavage Points in the Context of the SARS-CoV-2 Main and Papain-like Proteases. **2022**, 27, 8251 ○
- 352 Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands. **2022**, 9, 1

351	SARS-CoV-2 infection and COVID-19 in children. 2022,	0
350	Medical and chemical efficacy of respiratory physiotherapy and Remdesivir in patients with COVID-19 pneumonia: A systematic review and meta-analysis. 2022, 125, 713-720	0
349	Chronic Obstructive Pulmonary Disease is Not Associated with In-Hospital Mortality in COVID-19: An Observational Cohort Analysis. Volume 17, 3111-3121	0
348	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. 2022, 175, 1716-1727	1
347	Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. 2022,	0
346	Impact of Anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study.	0
345	Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients. 2022, 14, 2728	0
344	Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. 2023, 12,	0
343	PIONEER trial: favipiravir to treat moderate COVID-19. 2022,	0
342	Structural Characteristics of Heparin Binding to SARS-CoV-2 Spike Protein RBD of Omicron Sub-Lineages BA.2.12.1, BA.4 and BA.5. 2022, 14, 2696	1
341	Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses.	0
340	Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. 2022, 8,	3
339	Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. 2022, 58, 1848	1
338	Small molecules in the treatment of COVID-19. 2022, 7,	3
337	Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities. 2022,	0
336	Transplantation Amid a Pandemic: The Fall and Rise of Kidney Transplantation in the United States. 2023, 9, e1423	0
335	The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases. 2022, 11, 7342	0
334	Update on COVID-19 Therapy in Pediatric Age. 2022, 15, 1512	1

333	CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY. 2022 , 10, 432-445	1
332	Outcomes in Patients with Acute Hypoxemic Respiratory Failure Secondary to COVID-19 Treated with Noninvasive Respiratory Support versus Invasive Mechanical Ventilation.	0
331	Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2. 2022 , 105501	1
330	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. 2022 ,	0
329	Remdesivir-Induced Liver Injury in a Patient With Coronavirus Disease 2019 and History of Congestive Hepatopathy. 2022 ,	0
328	Effectiveness of Regdanvimab and Remdesivir in Patients with COVID-19 at a Single Hospital. 2022 , 12, 340-345	0
327	Clinical outcomes of COVID-19 caused by the Alpha variant compared with one by wild type in Kobe, Japan. A multi-center nested case-control study. 2022 ,	0
326	SARS-CoV-2 RNA and viable virus contamination of hospital emergency department surfaces and association with patient COVID-19 status and aerosol generating procedures.	0
325	Assessment of the pneumonia severity score in community-acquired and nursing and healthcare-associated pneumonia due to COVID-19. 2022 ,	0
324	The role of ECMO in COVID-19 acute respiratory failure: Defining risk factors for mortality. 2022 ,	0
323	Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study. 2022 , 4, e0799	1
322	Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study. 13,	4
321	Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. 2022 , 2, 1758-1767	0
320	SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. 2022 , 10, 2145	1
319	Repurposing of Chemotherapeutics to Combat COVID-19. 2022 , 22, 2660-2694	1
318	Management of COVID-19 Infection in Pregnancy. 2022 ,	0
317	Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection.	0
316	Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.	0

315	Probing the neuro-psychological changes observed with the administration of COVID-19 Drugs. 2022 , 23,	1
314	Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study. 1-15	0
313	Therapeutic potential of compounds targeting SARS-CoV-2 helicase. 10,	0
312	Cardiovascular Side Effects of Neuraminidase Inhibitors: A Review. 2023 , 10-17	0
311	Direct Nasal Swab for Rapid Test and Saliva as an Alternative Biological Sample for RT-PCR in COVID-19 Diagnosis. 2022 , 10,	1
310	Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease.	0
309	Lopinavir/ritonavir for Treatment of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial. 2022 ,	0
308	Development of novel monoclonal antibodies against nsp12 of SARS-CoV-2. 2022 , 19,	0
307	Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein. 2022 , 96,	0
306	FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.	8
305	Long-term Follow-up After Critical COVID-19.	0
304	2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses.	0
303	Characteristics and Outcomes by Ceiling of Care of Subjects Hospitalized with COVID-19 During Four Waves of the Pandemic in a Metropolitan Area: A Multicenter Cohort Study.	0
302	Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States. 2022 , 5, e2244505	2
301	Pharmacological Effects and Clinical Prospects of Cepharanthine. 2022 , 27, 8933	0
300	Safety and outcomes of an early discharge strategy with oxygen home therapy in stable severe COVID-19 patients. 1-7	0
299	Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: A propensity score adjusted retrospective cohort study. 2023 , 95,	0
298	Liver transplantation amidst the COVID-19 era: Our center's experience. 11, 316-321	0

- 297 Ethics of Expanded Access During the COVID-19 Pandemic. **2023**, 367-384 ○
- 296 Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae. **2023**, 44, 066-074 ○
- 295 Effect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study. **2023**, 18, e0267339 ○
- 294 Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. 9, ○
- 293 The Rationale for Using Corticosteroids in COVID-19 Encephalopathy: Lessons From a Case Report With Evidence From Literature. **2023**, ○
- 292 Frailty and hyperactive delirium in hospitalized older patients with COVID-19: an insight from GeroCovid registry. ○
- 291 Evolving pharmaceutical therapies for confronting COVID-19: An overview. **2022**, ○
- 290 Remdesivir Use in Low Weight, Premature, and Renally Impaired Infants With SARS-CoV-2 Infection in Sheikh Khalifa Medical City, UAE: Case Series. **2023**, ○
- 289 Use of Antiviral Agents and other Therapies for COVID-19. **2023**, 44, 118-129 ○
- 288 HIV and COVID-19 Disease. **2023**, 44, 035-049 ○
- 287 Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study. ○
- 286 An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia. 1
- 285 The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial. 108155892211418 ○
- 284 Learning how to treat coronavirus disease 2019 in hematopoietic stem cell transplant patients. ○
- 283 Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan. ○
- 282 A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2. **2023**, 13, ○
- 281 Better design leads to better results Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019. ○
- 280 The outcome of Covid-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia, Single Center Experience. **2023**, ○

- 279 NRbDMF: A Recommendation Algorithm for Predicting Drug Effects Considering Directionality. ○
- 278 Genome Structure, Life Cycle, and Taxonomy of Coronaviruses and the Evolution of SARS-CoV-2. **2023**, 305-339 ○
- 277 Informative Censoring: A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data. **2023**, 13, 210 1
- 276 Pharmacological Activities of Fingerroot Extract and Its Phytoconstituents Against SARS-CoV-2 Infection in Golden Syrian Hamsters. Volume 15, 13-26 ○
- 275 A Selective SARS-CoV-2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species. ○
- 274 References. **2023**, 383-393 ○
- 273 Racial inequality in COVID-treatment and in-hospital length of stay in the US over time. 10, ○
- 272 Multi-OMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells. **2023**, 26, 105895 ○
- 271 Integrated Data Analysis Uncovers New COVID-19 Related Genes and Potential Drug Re-Purposing Candidates. **2023**, 24, 1431 ○
- 270 Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study. 13, ○
- 269 Treatment of infection and inflammation associated with COVID-19, multi-drug resistant pneumonia and fungal sinusitis by nebulizing a nanosilver solution. **2023**, 102654 ○
- 268 Anthracyclines inhibit SARS-CoV-2 infection. ○
- 267 Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. **2023**, 9, ○
- 266 A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. **2023**, 43, ○
- 265 COVID-19 in der Intensivmedizin. **2023**, 18, 32-41 ○
- 264 Commentary on COVID-19-induced liver injury in various age and risk groups. 12, 44-52 ○
- 263 Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine. **2023**, 27, 6-14 ○
- 262 In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from *Thymus schimperi*. Volume 16, 1-13 ○

261	Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting. 2023 , 3,	0
260	Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand. 9,	1
259	Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19. 2023 , 11, 145	0
258	Spray freeze dried niclosamide nanocrystals embedded dry powder for high dose pulmonary delivery. 2023 , 415, 118168	0
257	Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score. 2023 , 78, 102188	0
256	Hospital at home treatment with remdesivir for patients with COVID-19: real-life experience. 2023 , 127, 124-128	1
255	Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models. 2023 , 153, 106491	0
254	The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19. 2023 , 77, 101777	0
253	Cardiovascular Post-Acute COVID-19 Syndrome: Definition, Clinical Scenarios, Diagnosis, and Management.	0
252	Nasal Microbiome in COVID-19: A Potential Role of Corynebacterium in Anosmia. 2023 , 80,	0
251	COVID-19: Cardiology Perspective. 2023 , 361-388	0
250	Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. 2022 , 17, e0278963	0
249	Experience of Using Remdesivir in Patients with Novel Coronavirus Infection. 2022 , 10, 365-380	0
248	COVID-19: Nursing Perspective. 2023 , 454-471	0
247	Perforation of the Diverticulum in the Sigmoid Colon Following Administration of Tocilizumab for Treatment of Coronavirus Infection-Associated Pneumonia: A Case Report. 2022 , 55, 780-785	0
246	Pharmacologic Therapeutics for COVID-19. 2023 , 290-318	0
245	Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. 2022 , 21, 1483-1494	0
244	COVID-19 in Pediatrics. 2023 , 255-289	0

243	COVID-19: Inpatient Management. 2023 , 182-232	0
242	The Comparison of Clinical Epidemiology of Hospitalized Patients with COVID-19 during the Third and Fourth Waves of the Pandemic in Gorgan. 2022 , 2022, 1-6	0
241	The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic.	1
240	Defining neutralization and allosterity by antibodies against COVID-19 variants.	0
239	COVID-19-associated myocardial injury: A case report.	0
238	Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation. Publish Ahead of Print,	1
237	Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. 2023 , 99-139	0
236	International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship. 12,	0
235	Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized COVID-19 patients: real-world data from resource-limited country. 2023 ,	1
234	COVID-19: Diabetes Perspective Pathophysiology and Management. 2023 , 12, 184	1
233	Peripheral Blood Genes Crosstalk between COVID-19 and Sepsis. 2023 , 24, 2591	0
232	Comparative admission rates and infection severity of COVID-19 among unvaccinated and vaccinated patients. 108155892211491	0
231	Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease. 2023 , 13, 378	0
230	Coronavirus Pandemics. 2023 , 143-222	0
229	Efficient Targeted Delivery of Bifunctional Circular Aptamer-ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation. 2207066	0
228	In silico study of mechanism of neem leaf (<i>Azadirachta indica</i>) active compound inhibits SARS CoV2 infection through inhibition of ACE2 and CD209 receptors. 2023 ,	0
227	COVID-19 and the liver: Are footprints still there?. 29, 656-669	0
226	Qualitative interviews to evaluate content validity of the ACTIV-2 COVID-19 Symptom Diary (ACSD). 2023 , 7,	0

- 225 Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19. **2023**, 304-309
- 224 COVID-19 in Older Adults. **2023**, 1-19
- 223 COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. **2023**, 27,
- 222 The lung employs an intrinsic surfactant-mediated inflammatory response for viral defense.
- 221 A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. **2023**, 18, e0274243
- 220 Remdesivir for the treatment of COVID-19. **2023**, 2023,
- 219 Belimumab for the treatment of pediatric patients with lupus nephritis.
- 218 Deep Learning With Chest Radiographs for Making Prognoses in Patients With COVID-19: Retrospective Cohort Study (Preprint).
- 217 Infectious Disease Pearls for Maritime Surgical Teams. **2023**, 267-285
- 216 A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection.
- 215 Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine. **2023**, 66, 4150-4166
- 214 Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts.
- 213 Factors associated with viral rebound among COVID-19 patients receiving oral antivirals. **2023**,
- 212 Efficacy and Adverse Effects of Remdesivir in Patients with COVID-19 Pneumonia: A Retrospective Study.
- 211 A study protocol of external validation of eight COVID-19 prognostic models for predicting mortality risk in older populations in a hospital, primary care, and nursing home setting. **2023**, 7,
- 210 Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. **2023**, 31, 517-525
- 209 SARS-CoV-2-Induced Myocarditis: A State-of-the-Art Review. **2023**, 15, 916
- 208 Veklury[®] (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether- β -cyclodextrin content.

- 207 The impact of the self-recognition ability and physical quality on coupled negative information-behavior-epidemic dynamics in multiplex networks. **2023**, 169, 113229 ○
- 206 Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia. **2023**, 11, 100167 ○
- 205 Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro). **2023**, 251, 115226 ○
- 204 Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of ED-N4-hydroxycytidine (NHC) and a 3?-fluoro-substituted analogue of NHC. **2023**, 135, 106527 ○
- 203 Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. **2023**, 212, 107198 ○
- 202 Unraveling the mechanism of action of cepharanthine for the treatment of novel coronavirus pneumonia (COVID-19) from the perspectives of systematic pharmacology. **2023**, 16, 104722 ○
- 201 Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. ○
- 200 Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19. **2023**, 176, 556-560 ○
- 199 Are herbal medications, with possible beneficial effects for benign prostatic hyperplasia, better to be continued during the COVID-19 pandemic?. 039156032311623 ○
- 198 Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. **2023**, 58, 101889 ○
- 197 Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19. **2023**, 254, 115380 ○
- 196 Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors. **2023**, 80, 117179 1
- 195 The Data and Safety Monitoring Board: The Toughest Job in Clinical Trials. **2023**, 2, 1
- 194 Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India. **2023**, 11, 100154 ○
- 193 The development of COVID-19 treatment. 14, 2
- 192 Advances in the discovery of new chemotypes through ultra-large library docking. **2023**, 18, 303-313 ○
- 191 Comparison of Different Antiviral Regimens in the Treatment of Patients with Severe COVID-19: A Retrospective Cohort. **2023**, 59, 260 ○
- 190 Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. **2023**, 9, e13285 ○

- 189 Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections. **2023**, 12, 12 ○
- 188 Convalescent plasma for people with COVID-19: a living systematic review. **2023**, 2023, ○
- 187 Structural basis for substrate selection by the SARS-CoV-2 replicase. **2023**, 614, 781-787 ○
- 186 Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study. 14, ○
- 185 Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study. **2023**, 42, 310-314 ○
- 184 A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. **2023**, 11, 332 ○
- 183 Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches. **2023**, 95, ○
- 182 Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. ○
- 181 Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. **2023**, 18, e0281281 ○
- 180 COVID-19 diagnosis prediction using classical-to-quantum ensemble model with transfer learning for CT scan images. **2021**, 69, 319-333 ○
- 179 Corticosteroids and Outcomes in Solid Organ Transplant Recipients Infected With Severe Acute Respiratory Syndrome Coronavirus 2. **2023**, 7, 99-108 ○
- 178 Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells. **2023**, 211, 105550 ○
- 177 Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19. **2023**, 3, 198-217 ○
- 176 Pleiotropic Functions of Nitric Oxide Produced by Ascorbate for the Prevention and Mitigation of COVID-19: A Reevaluation of Pauling's Vitamin C Therapy. **2023**, 11, 397 ○
- 175 A COVID Dilemma: How to Manage Pregnancies in Case of Severe Respiratory Failure?. **2023**, 11, 486 ○
- 174 Nucleoside Analogs That Inhibit SARS-CoV-2 Replication by Blocking Interaction of Virus Polymerase with RNA. **2023**, 24, 3361 ○
- 173 COVID-19 and Acute Ischemic Stroke Mortality and Clinical Outcomes among Hospitalized Patients in the United States: Insight from National Inpatient Sample. **2023**, 12, 1340 ○
- 172 The Role of Nutrition in Mitigating the Effects of COVID-19 from Infection through PASC. **2023**, 15, 866 ○

- 171 Therapeutic options in COVID-19. **2023**, 647-672 ○
- 170 Communicable diseases. **2023**, 215-366 ○
- 169 Palliative Care in a Pandemic: A Multicenter Cohort of Critically Ill Patients with Coronavirus Disease 2019. **2023**, 24, 190-198 ○
- 168 Oral ketone esters acutely improve myocardial contractility in post-hospitalized COVID-19 patients: A randomized placebo-controlled double-blind crossover study. 10, ○
- 167 How to use COVID-19 antiviral drugs in patients with chronic kidney disease. 14, ○
- 166 Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence. **2023**, 10, 350 ○
- 165 Relation of COVID-19 with liver diseases and their impact on healthcare systems: The Portuguese case. 29, 1109-1122 ○
- 164 Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP. **2023**, 12, 1388 ○
- 163 Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 community, highly vaccinated patients with high risk for severe disease: Evidence that both antivirals reduce the risk for disease progression and death. ○
- 162 Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. ○
- 161 Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. ○
- 160 Impact of COVID-19 on Cardiovascular Disease. **2023**, 15, 508 ○
- 159 Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave. **2023**, ○
- 158 Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID-19?. **2023**, 23, ○
- 157 Potential Mechanisms of Perillae folium Against COVID-19: A Network Pharmacology Approach. ○
- 156 Synthesis of conjugates of (αR,7S)-colchicine with monoterpenoids and investigation of their biological activity. **2023**, 72, 248-262 ○
- 155 Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. **2023**, 6, e2255815 ○
- 154 Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2. **2023**, 13, 359 ○

- 153 Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. **2023**, 15, 159 ○
- 152 Severe Acute Respiratory Syndrome and Particulate Matter Exposure: A Systematic Review. **2023**, 13, 538 ○
- 151 Deep Learning With Chest Radiographs for Making Prognoses in Patients With COVID-19: Retrospective Cohort Study. 25, e42717 ○
- 150 Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities. ○
- 149 Current and Emerging Therapies for COVID-19 in Lung Transplantation. ○
- 148 A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma. ○
- 147 Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination. **2023**, 17, 101-107 ○
- 146 Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. **2023**, 15, 549 ○
- 145 Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS -441524 in patients with moderate and severe COVID -19. **2023**, 12, 513-521 ○
- 144 Clinical outcomes of children and adolescents with sickle cell disease and COVID-19 infection: A year in review at a metropolitan tertiary pediatric hospital. 10, ○
- 143 Structural insights into ribonucleoprotein dissociation by nucleocapsid protein interacting with non-structural protein 3 in SARS-CoV-2. **2023**, 6, ○
- 142 Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test. **2023**, 29, 539-545 ○
- 141 Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. **2023**, 13, 309 ○
- 140 Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients. **2023**, 7, e0034-e0034 ○
- 139 Repurposing anthocyanins into potential inhibitors of the SARS-CoV-2 main protease (Mpro): An in silico approach. **2023**, ○
- 138 Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: A Joint Evidence-Based Guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). ○
- 137 Remdesivir saves lives. Were 3 years needed to learn that?. **2023**, ○
- 136 Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. **2023**, ○

- 135 Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. 14, ○
- 134 Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19. **2023**, 13, 617 ○
- 133 An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. **2023**, 9, e13952 ○
- 132 Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401 ○
- 131 A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine. **2023**, 11, 515 ○
- 130 Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19. **2023**, 95, 66-77 ○
- 129 Comparison of patients admitted to an inner-city intensive care unit across 3 COVID-19 waves. **2023**, 102, e33069 ○
- 128 Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial. 10, ○
- 127 In Vitro Pharmacokinetic Behavior of Antiviral 3-Amidinophenylalanine Derivatives in Rat, Dog and Monkey Hepatocytes. **2023**, 11, 682 ○
- 126 Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. **2023**, 13, e067910 ○
- 125 Machine learning on large scale perturbation screens for SARS-CoV-2 host factors identifies Ecatenin/CBP inhibitor PRI-724 as a potent antiviral. ○
- 124 Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. **2023**, 18, e0279765 ○
- 123 Rising Mortality in Coronavirus-19 Patients Supported With Extracorporeal Membrane Oxygenation. **2023**, 69, 254-259 ○
- 122 Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID19) - Analysis of data from daily practice. ○
- 121 Safety and Biodistribution of Nanoligomers Targeting the SARS-CoV-2 Genome for the Treatment of COVID-19. **2023**, 9, 1656-1671 ○
- 120 Single-Center Experience With the Seraph-100[®] Microbind[®] Affinity Blood Filter in Patients With SARS-CoV-2 Infection and Septic Shock at a Military Treatment Facility. ○
- 119 Mechanical Circulatory Support in COVID-19. **2023**, 19, 205-211 ○
- 118 CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2. **2023**, 12, 776 ○

- 117 Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery Genetics Alliance Perspective. **2023**, 66, 3664-3702 ○
- 116 Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen. **2023**, 18, 122-135 ○
- 115 Development of an External Control Arm Using Electronic Health Record-Based Real-World Data to Evaluate the Efficacy of COVID -19 Treatment. ○
- 114 A Scoping Review of the Impact of COVID-19 on Kidney Transplant Patients in the United States. **2023**, ○
- 113 Type I interferon signaling induces a delayed antiproliferative response in Calu-3 cells during SARS-CoV-2 infection. ○
- 112 Effects of Antidepressants on COVID-19 Outcomes: Retrospective Study on Large-Scale Electronic Health Record Data. 12, e39455 ○
- 111 Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease. ○
- 110 Application of machine learning approach in emergency department to support clinical decision making for SARS-CoV-2 infected patients. **2023**, 1 ○
- 109 Treating COVID-19: Targeting the Host Response, Not the Virus. **2023**, 13, 712 ○
- 108 Clinical efficacy of probiotics in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. 1-8 ○
- 107 Pharmacological potential of *Withania somnifera* (L.) Dunal and *Tinospora cordifolia* (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. 14, ○
- 106 SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequelae. ○
- 105 Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX IREVOlUTION trial. **2023**, 20, 100466 ○
- 104 Reactive oxygen species are associated with the inhibitory effect of N-(4-hydroxyphenyl)-retinamide on the entry of the severe acute respiratory syndrome-coronavirus 2. ○
- 103 Artificial Intelligence Neural Network Consistently Interprets Lung Ultrasound Artifacts in Hospitalized Patients: A Prospective Observational Study. ○
- 102 Identification and Prediction of Clinical Phenotypes in Hospitalized COVID-19 Patients (Preprint). ○
- 101 SARS-CoV-2 in Pregnancy, Birth and Puerperium. Guideline of the DGGG und DGPM (S2k-Level, AWMF Registry Number 015/092, March 2022). ○
- 100 The main treatments used for SARS-CoV-2 patients. **2022**, 3, 095-103 ○

- 99 Therapeutic potential of salicylamide derivatives for combating viral infections. ○
- 98 Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. **2023**, 95, ○
- 97 Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. **2023**, 55, 351-360 ○
- 96 Cancer, more than a COVID-19 co-morbidity¹³, ○
- 95 Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. 10, ○
- 94 Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives. **2023**, 15, 941 ○
- 93 Enhanced Remdesivir Analogues to Target SARS-CoV-2. **2023**, 28, 2616 ○
- 92 Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. **2023**, ○
- 91 Drug treatment of COVID-19 infection. **2023**, 29, 174-183 ○
- 90 Effectiveness of Fortified Garlic Extract Oral Capsules as Adjuvant Therapy in Hospitalized Patients with Coronavirus Disease 2019: A Triple-Blind Randomized Controlled Clinical Trial. **2023**, 98, 100699 ○
- 89 The role of interleukin 13 and the type 2 immune pathway in COVID-19. **2023**, 1 ○
- 88 Role of TGF- β Signaling in Coronavirus Disease 2019. **2022**, 9, 9 ○
- 87 Unconventional Products for COVID-19 Prevention: Practices, Experiences and Perceptions of Frontline Workers in Borno State, Nigeria. ○
- 86 Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province. **2023**, ○
- 85 G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters. 10, ○
- 84 COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study. 2, ○
- 83 Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia. ○
- 82 High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. **2023**, 25, ○

- 81 Steroid Pulse Therapy as a Treatment for Patients With COVID-19 Pneumonia at an Intensive Care Unit: A Single-Center Retrospective Observational Study. **2023**, ○
- 80 Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings. **2023**, 12, 2371 ○
- 79 Potency assessment of IFN γ -producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects. **2023**, 6, e202201759 ○
- 78 Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. **2023**, ○
- 77 COVID-19 Management Strategies in Solid Organ Transplant Recipients. **2023**, ○
- 76 Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives. **2023**, 0 ○
- 75 Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting. **2023**, 15, 811 ○
- 74 Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. 14, ○
- 73 Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids. **2023**, 20, 2276-2287 ○
- 72 The SARS-CoV-2 Pandemic: What are the Limits and Promises of Technical Mitigation Instruments Available to Humanity?. 36, 1439-1445 ○
- 71 The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions and Implications. **2023**, ○
- 70 Immune Response in COVID-19-associated Acute Kidney Injury and Maladaptive Kidney Repair. **2023**, 10, ○
- 69 Impact of Drug Repurposing on SARS-Cov-2 Main Protease. **2022**, 96, 3311-3330 ○
- 68 Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19. **2023**, 11, 932 ○
- 67 Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study. ○
- 66 Multi-institutional experience with COVID-19 convalescent plasma in children. ○
- 65 Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients. **2023**, 13, ○
- 64 Remdesivir-Induced Bradycardia. **2023**, 116, 317-320 ○

- 63 A comment-driven evidence appraisal approach to promoting research findings into practice when only uncertain evidence is available. **2023**, 21, ○
- 62 Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. **2023**, 19, e1011231 ○
- 61 Decreased Gas6 and sAxl Plasma Levels Are Associated with Hair Loss in COVID-19 Survivors. **2023**, 24, 6257 ○
- 60 Report of consensus panel 5 from the 11th international workshop on Waldenström's macroglobulinemia on COVID-19 prophylaxis and management. **2023**, ○
- 59 Non-coding RNAs derived from the foot-and-mouth disease virus genome trigger broad antiviral activity against coronaviruses. 14, ○
- 58 Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. 11, 2140-2159 ○
- 57 Biomimetic SARS-CoV-2 Spike Protein Nanoparticles. ○
- 56 Outpatient medications associated with protection from COVID-19 hospitalization. **2023**, 18, e0282961 ○
- 55 Remdesivir use and antimicrobial stewardship restrictions during the coronavirus disease 2019 (COVID-19) pandemic in the United States: A cross-sectional survey. **2023**, 3, ○
- 54 Treatment of COVID-19 pneumonia with low-dose radiotherapy plus standard of care versus standard of care alone in frail patients. ○
- 53 Respiratory and other systemic complications of coronavirus disease 2019 in adults: A narrative review. 2, ○
- 52 Learning from real world data about combinatorial treatment selection for COVID-19. 6, ○
- 51 O-, N- and C-bicyclopentylation using thianthrenium reagents. ○
- 50 COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. **2023**, 12, 545 ○
- 49 The Influence of the Health Belief Model on the Decision to Get the COVID-19 Vaccine: An International Survey Study of College Students. **2023**, 60, 004695802311642 ○
- 48 A Review of Pathology and Analysis of Approaches to Easing Kidney Disease Impact: Host-Pathogen Communication and Biomedical Visualization Perspective. **2023**, 41-57 ○
- 47 Early symptoms preceding post-infectious irritable bowel syndrome following COVID-19: a retrospective observational study incorporating daily gastrointestinal symptoms. **2023**, 23, ○
- 46 Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. **2023**, 58, 101939 ○

- 45 Therapeutics for COVID-19. **2024**, 282-307 ○
- 44 Pulmonary Manifestations of COVID-19. **2024**, 100-136 ○
- 43 The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection. ○
- 42 Kidney Manifestations of COVID-19. **2024**, 203-217 ○
- 41 Severe COVID-19 and non-COVID-19 severe sepsis converge transcriptionally after a week in the intensive care unit, indicating common disease mechanisms. 14, ○
- 40 COVID-19: Natural History and Spectrum of Disease. **2024**, 72-98 ○
- 39 SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice. ○
- 38 Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19. **2023**, 6, e237243 ○
- 37 COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. **2023**, 4, ○
- 36 Current Strategies to Combat COVID-19. **2023**, 361-374 ○
- 35 Simultaneous hypothesis testing for multiple competing risks in comparative clinical trials. ○
- 34 Safety and Efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial. **2023**, 100706 ○
- 33 Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor Biased Ligand in Adults With COVID-19. **2023**, 329, 1170 ○
- 32 Lung transplantation for coronavirus disease 2019 acute respiratory distress syndrome/fibrosis: silver lining of a global pandemic. Publish Ahead of Print, ○
- 31 1-O-Octadecyl-2-O-benzyl-sn-glycerol-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity. ○
- 30 VITAS, a sensitive in vivo selection assay to discover enzymes producing antiviral natural products. ○
- 29 Modulation of in Vitro SARS-CoV-2 Infection by *Stephania tetrandra* and Its Alkaloid Constituents. ○
- 28 Phytochemicals of *Withania somnifera* as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. **2023**, 11, 1000 ○

- 27 Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147. ○
- 26 Acute kidney injury in COVID-19 patients receiving remdesivir: a systematic review and meta-analysis of randomized clinical trials. **2023**, 100200 ○
- 25 Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors. **2023**, 16, 585 ○
- 24 A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. **2023**, 9, ○
- 23 Exploring m6A-RNA methylation as a potential therapeutic strategy for acute lung injury and acute respiratory distress syndrome. **2023**, 13, ○
- 22 Race-based reporting and participation of Black individuals in registered pain clinical trials, United States, 2000 to 2019. **2023**, Publish Ahead of Print, ○
- 21 The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. **2023**, 15, 976 ○
- 20 Epidural Abscesses as a Complication of Interleukin-6 Inhibitor and Dexamethasone Treatment in a Patient with COVID-19 Pneumonia: A Case Report. **2023**, 59, 771 ○
- 19 A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo. ○
- 18 The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model. **2023**, 23, ○
- 17 REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT. ○
- 16 Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. ○
- 15 Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review. **2023**, 12, ○
- 14 Use of anti-viral therapies in hospitalised COVID-19 patients in the United Arab Emirates: a cost-effectiveness and health-care resource use analysis. **2023**, 23, ○
- 13 Clinical Disease Characteristics and Treatment Trajectories Associated with Mortality among COVID-19 Patients in Punjab, Pakistan. **2023**, 11, 1192 ○
- 12 DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19. **2023**, 106969 ○
- 11 Immune enhancers for COVID-19. **2023**, 49-76 ○
- 10 What's new in flow biocatalysis? A snapshot of 2020-2022. 3, ○

- 9 Severe COVID-19 Myocarditis in a Young Unvaccinated Patient. **2023**, ○
- 8 Resultados en la práctica asistencial y coste marginal del tratamiento con tocilizumab en pacientes COVID-19. **2023**, 47, 10-15 ○
- 7 COVID-19 and Multiorgan Response: The Long-Term Impact. **2023**, 101756 ○
- 6 [Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients. **2023**, 47, T10-T15 ○
- 5 Computational Screening of Inhibitory Compounds for SARS-Cov-2 3CL Protease with a Database Consisting of Approved and Investigational Chemicals. **2023**, 71, 360-367 ○
- 4 Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection. **2023**, ○
- 3 Viral dynamics of SARS-CoV-2 in immunocompromised patients. **2023**, ○
- 2 COMPARISON OF THE EFFECTIVENESS OF REMDESIVIR VERSUS FAVIPIRAVIR ON CLINICAL IMPROVEMENT AND MORTALITY AMONG PATIENTS WITH COVID-19 PNEUMONIA: A RETROSPECTIVE SINGLE-CENTER STUDY. 7, e0151 ○
- 1 Association Between Vaccination Status and Outcomes in Patients Admitted to the ICU With COVID-19. Publish Ahead of Print, ○